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THE MHEALTH CONUNDRUM: SMARTPHONES & MOBILE
MEDICAL ApPs-How MUCH FDA MEDICAL DEVICE
REGULATION IS REQUIRED?*
Vincent J. Roth*
Smariphones and tablets have provided a plethora of new business
opportunities for a number of industries, including healthcare.
Technology, however, appears to have outpaced the regulatory
environment, which has spawned criticism over the current
guidance of the Food and Drug Administration ("FDA") for
mobile medical applications. Commentators have remarked that
the FDA's guidance is complex and unclear. Smartphone
applications are so much more readily available than traditional
medical devices that a new and unaddressed issue of consumer
access to medical tools has emerged. This has put the power of
self-treatment back in the hands of citizens through a phenomena
referred to here as "marketplace interposition, " which creates
new safety implications. This Article explores the current FDA
regulatory scheme for mobile medical applications and adapters
for mobile devices designed to provide mobile healthcare, or
"mHealth, " and provides recommendations on how to improve the
FDA regulatory environment. While regulation of medical devices
is necessary to ensure safety, the inevitable increase in mHealth
and consumer access requires a more defined, targeted, and
streamlined regulatory scheme for mobile devices in order to keep
pace with this quickly evolving technology.
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I. INTRODUCTION
Mobility in today's society is not only a fact of life, but a
booming opportunity for business. Mobile devices, particularly
smartphones, have provided a plethora of new business
opportunities for a number of industries including healthcare. The
increasing availability of mobile devices and high-speed data
transmission to and from these devices has generated a demand for
convenience from healthcare providers and consumers.' This
heightened demand has garnered the attention of device and
software developers wishing to capitalize on the growing mobile
health market.2 Greater activity in "the use of mobile
telecommunications in healthcare," or "mHealth,"' has drawn the
attention of regulators, which has spawned debate over Food and
Drug Administration ("FDA") medical device regulation for
mHealth products.
This Article examines the developing mHealth industry and
related medical device regulation. Particular attention is given to
the emerging but unclear stance of the FDA with regard to
smartphones, software applications, and adapters. The current
regulatory regime consists of several overlapping analyses that
device developers and device manufacturers need to conduct with
regard to their products. A threshold question for these industry
participants is whether a smartphone, application, or adapter is a
medical device.' Determining whether a product is a medical
Tatiana Melnik, There's an App for That! The FDA Offers a Framework for
Regulation Mobile Health, J. HEALTH CARE COMPLIANCE, Sept.-Oct. 2011, at
55.
2 Patricia Mechael & Sarah Struble, Healthcare by Numbers: Using Mobile
Phones to Save Lives, UCA NEWS (Mar. 21, 2013), http://www.ucanews.com/
news/healthcare-by-numbers-using-mobile-phones-to-save-lives/67799.
3 Deborah Runkle, The mHealth Revolution, SCITECH LAW (Winter/Spring)
http://www.americanbar.org/content/dam/aba/publications/gp solo magazine/ju
ly august/gpsolo issue 2013july august_304.authcheckdam.pdf.
Vernessa T. Pollard & Chandra Branham, FDA Medical Device Requirements:
A Legal Framework for Regulating Health Information Technology, Software,




device is key because if it is not, then medical device regulations
are not applicable.
With regard to FDA regulation, if the object at issue is a
medical device, the developer or manufacturer must evaluate
various layers of analysis including any approval from the FDA
that may be required before lawfully putting the device on the
market. The first inquiry considers under which one of the three
FDA classifications the object belongs-Class I, Class II, or Class
111-based on the potential health risks to the public.' These
classifications designate the level of control needed in order to
provide the FDA with reasonable assurance of the product's safety
and effectiveness.6 The regulatory control requirements a medical
device must meet are typically determined by its classification.
Often, however, the control requirements placed on a medical
device do not completely align with the classification scheme.'
Hence, developers and manufacturers must also consider whether
FDA control measures are pertinent.! Adding to this mix is the fact
that every device these days involves some software, and in the
case of an application, it may be purely software. Further inquiry
arises when software and applications are involved. Apart from its
classification, if a device contains software, developers and
manufacturers must consider which FDA "level of concern" the
software presents to users.' Then, if an application is for a medical
device or causes a general device to become a medical device, the
software must be evaluated against the FDA's recent guidance on
'Id. at 3.
6 Regulatory Controls (Medical Devices), U.S. FOOD & DRUG ADMIN., http://
www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Overview/Genera
landSpecialControls/default.htm (last updated Apr. 11, 2013).
7 Telephone Interview with Anil Bhalani, Principal RA Consultant, Extomed,
LLC (June 28, 2013).
8id.
9 Guidance for the Content of Premarket Submissions for Software Contained
in Medical Devices, U.S. FOOD & DRUG ADMIN. (May 11, 2005), http://www.
fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/
ucm089543.htm.
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mobile medical applications.'o These multiple and overlapping
inquiries present burdensome complexity for developers and
device manufacturers.
The FDA tends to provide broad guidance to medical device
regulation." Because guidance is so broad, commentators indicate
that the regulatory terrain is uncertain with regard to mobile
medical application developers.12 For example, the FDA has stated
that it will exercise discretion as to whether it will enforce certain
regulations when regulating mobile medical applications that may
present a low risk, yet it fails to explain when it will exercise such
discretion." In areas where the FDA has indicated it would
exercise discretion, the FDA could better define the characteristics
and circumstances that warrant discretion so that developers can
better understand when compliance is required.
Complicating the inquiry into what regulations are pertinent for
a particular product is the fact that mobile medical applications are
so widely prevalent and readily available that consumers have far
greater access to them than consumers have had with traditional
'o Mobile Medical Applications: Guidance for Industry and Food and Drug
Administration Staff, U.S. FOOD & DRUG ADMIN. et al. 7-8 (Sept. 25, 2013),
available at http://www.fda.gov/downloads/MedicalDevices/DeviceRegulation
and Guidance/GuidanceDocuments/UCM263366.pdf (initially issued in draft
form on July 21, 2011 entitled "Draft Guidance for Industry and Food and Drug
Administration Staff: Mobile Medical Applications" [hereinafter "FDA Draft
Guidance for Medical Apps"], which was more recently revised and issued in
final form on September 25, 2013) [hereinafter "FDA Final Guidance for
Medical Apps"]; Draft Guidance for Industry and Food and Drug
Administration Staff Mobile Medical Applications, U.S. FOOD & DRUG ADMIN.
et al., (July 21, 2011), http://www.genomicslawreport.com/wp-content/uploads/
2013/03/FDA-mHealth-Draft-Guidance.pdf.
"Telephone Interview with Anil Bhalani, supra note 7.
2 See generally Bradley Merrill Thompson et al., A Call for Clarity: Open
Questions on the Scope of FDA Regulation of mHealth, MHEALTH REG. COAL.
(Dec. 22, 2010), available at http://mhealthregulatorycoalition.org/wp-content/
uploads/2010/12/mrcwhitefinal122210.pdf (describing how certain software with
specifically defined features has been regulated as a medical device, but that
current FDA guidance has "not finalized several rules that would establish basic
guidelines for the regulation of software" which then leads to uncertainty
regarding how some software might be regulated).
'3 Scott D. Danzis & Christopher Pruitt, Rethinking the FDA 's Regulation of
Mobile Medical Apps, SCITECH LAW, Winter/Spring 2013, at 26, 27.
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medical devices. Commentators, Congress, and the FDA have yet
to address the unprecedented access consumers have to
applications that can assist with the delivery of healthcare.
Consumers are availing themselves of healthcare tools that perform
functions akin to medical devices previously reserved to medical
practitioners-tools that consumers now use on themselves and
others to address medical issues. Is this the return of the right to
self-treatment? Consumer access instigates the unauthorized
practice of medicine. To what extent does society want consumers
to provide healthcare to themselves or others?
Related to consumer access is the concept of the actual use of
article device. At present, the FDA looks at how a manufacturer
intends its product to be used.14 It is questionable whether the FDA
principle of "intended use" still makes sense when applied to a
product that is deployed for an intended purpose of the
manufacturer as demonstrated in its product claims, but is utilized
in a way that is possibly unintended or unexpected by the
manufacturer.
The current regulatory landscape for medical devices, with its
focus on intended use rather than actual use, seems to provide a
loophole for mobile devices because there is no gatekeeping
through prescriptions or pharmacies for mobile medical
applications." Moreover, public discussion does not demonstrate
concern over off-label use with mHealth products, as is prevalent
in the pharmaceutical industry.'" Does medical device regulation
turn a blind eye to actual use? Current FDA regulation focuses on
the device itself, but more attention also needs to be given to the
effects of consumer access and actual use, otherwise the system
cannot be properly improved.
The presence of consumer access, self-treatment, the
unauthorized practice of medicine, and actual use, along with the
absence of these concepts in regulatory discourse have coalesced
14 Pollard & Branham, supra note 4, at 3.
Telephone Interview with Anil Bhalani, supra note 7.
16 George Lasezkay, Professor of Law, Pharmaceutical Law & Policy Class
Lecture at the University of San Diego School of Law (Feb. 7, 2013) (lecturer's
notes on file with author).
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into a phenomenon referred to here as "marketplace interposition."
Marketplace interposition occurs where commerce (in this case
technological advancement) encourages society to tacitly permit
self-treatment and the unauthorized practice of medicine through
consumer access and actual use. This Article recommends a more
targeted focus on consumer safety, which is the central purpose
behind all FDA regulation. The concepts behind marketplace
interposition all bear on patient safety. These cannot be ignored if
practical discussions are to be had regarding the appropriate level
of regulation. Simply looking at the device cannot ensure safety.
Targeting the right concepts pertaining to how a device is used will
yield better solutions.
In light of the various overlapping inquiries required when
evaluating a product under medical device regulation, this Article
recommends streamlining the regulations for simplicity and
consistency.
Congress also recognizes the need to improve the regulatory
landscape." Congress recently charged the FDA, under the Food
and Drug Administration Safety and Innovation Act of 2012
("FDASIA"), with the task of implementing measures that will
promote innovation while maintaining safety."
Part II of this Article reviews the entrance of smartphones into
mHealth. Part III studies the current FDA medical device
regulation. Part IV examines various forms of smartphone mHealth
products. Part V provides recommendations on how to improve the
regulation of mHealth products. While regulation of medical
devices is necessary to ensure safety, the inevitable increase in
mHealth and consumer access requires a more defined, targeted,
and streamlined regulatory scheme for mobile devices in order to
keep pace with this quickly evolving technology.
II. THE ADVENT OF SMARTPHONES AND MOBILE HEALTH
While mobile telephones are commonplace in today's society,
mobile telephones capable of viewing websites and data through
17 See Food and Drug Administration Safety and Innovation Act, 112 Pub. L.
No. 144, 126 Stat. 993 (2012).
" Id. § 618(a).
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various cellular networks, so called "smartphones," only began to
emerge in 1997 when Stockholm Smartphone released the Sony
Ericsson GS88.19 Then Research In Motion came along with
BlackBerry devices in 1999, which gained wide popularity shortly
after the turn of the century.2 0 Soon thereafter, Apple, Inc. entered
the mobile phone business when it launched the first iPhone on
June 29, 2007.21 That same month, Apple announced that third
parties could develop applications to run on the iPhone.2 2 This
announcement opened the door for the mobile applications
market,23 and it has been flourishing ever since. As of January
2013, there were over 775,000 iPhone applications, 24 about the
same for Android phones (estimated to have reached one million
by June, 2013),25 and about 100,000 applications for
BlackBerries.26
In addition to the ubiquity of mobile applications is the
pervasiveness of mobile phones. As of September, 2013, 91% of
adults in the United States owned a mobile phone and 55% owned
a smartphone.27 Moreover, also as of September, 2013, 74% of
'9 History, STOCKHOLM SMARTPHONE, http://www.stockholmsmartphone.org/
history/ (last visited Mar. 30, 2013).
20 The History of the Blackberry, BBGEEKS (Apr. 15, 2008), http://archive.is/
3Cln (accessed by searching for "BBGeeks" in the Internet Archive Index).
21 iPhone 2G, IPHONE HISTORY, http://www.iphonehistory.com/iphone-2g/
(last visited Mar. 30, 2013).
22 Press Release, Apple Inc., iPhone to Support Third-Party Web 2.0
Applications (June 11, 2007), available at http://www.apple.com/pr/library/2007/
06/1 liPhone-to-Support-Third-Party-Web-2-0-Applications.html.
23 Alex Krouse, Note, iPads, iPhones, Androids, and Smartphones: FDA
Regulation of Mobile Phone Applications as Medical Devices, 9 IND. HEALTH L.
REv. 731, 734 (2012).
24 Sam Costello, How Many Apps Are in the iPhone App Store, ABOUT.COM,
http://ipod.about.com/od/iphonesoftwareterms/qt/apps-in-app-store.htm (last visited
Mar. 31, 2013).
25 Dan Rowinski, Google Play Will Beat Apple App Store to 1,000,000 Apps,
READWRITE (Jan. 8, 2013), http://readwrite.com/2013/01/08/google-play-to-hit-
1 -million-apps-before-apple-app-store.
26 Mark Jones, BlackBerry App World Re-Branded Ahead of BB1O Launch,
RETHINK WIRELESS (Jan 22, 2013), http://www.rethink-wireless.com/2013/01/
22/blackberry-app-world-re-branded-ahead-bb 1 0-launch.htm.
27 Joanna Brenner, Pew Internet: Mobile, PEW INTERNET (Jan. 31, 2013),
http://pewinternet.org/Commentary/2012/February/Pew-Internet-Mobile.aspx.
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U.S. adults had either a tablet or "e-reader." 28 The rest of the world
revealed a similar profile. The International Telecommunications
Union of the United Nations reported that when the global
population reached 7 billion people in 2011, there were
approximately 6 billion mobile phone subscriptions worldwide.29
Mobile applications have noticeably migrated into the
healthcare industry." 81% of U.S. adults use the Internet and of
these, 72% reported to have searched online for health information
in 2012, thus, approximately 59% of all U.S. adults access health
information online.3' Furthermore, 31% of mobile phone owners
are reported to use their phones for health or medical information.32
Manhattan Research determined that 64% of physicians used
smartphones in their daily lives, personally and professionally, by
the end of 2011, and it is estimated that as of 2013, 81% of
physicians use smartphones." This research indicates that
consumers want healthcare information, mobile phones are
becoming pervasive, and physicians are also gravitating to
smartphones, which have much greater capabilities than traditional
mobile phones. The pervasiveness of mobile devices has brought
about the mobile health industry.
The proliferation of mobile phones has caught the attention of
global health experts, developers, innovators, and entrepreneurs. 34
Collectively, these players have formed a movement called
"mobile health," or "mHealth," to capitalize on the potential mobile
devices have to deliver healthcare." Mobile health applications are
integral to mHealth because they facilitate the provision of
healthcare compared to standard and common hand-held
28 Id
29 Mechael & Struble, supra note 2.
30 Krouse, supra note 23, at 738.
31 SUSANNAH Fox & MAEVE DUGGAN, HEALTH ONLINE 2013 (Jan. 15, 2013),
available at http://pewinternet.org/~/media//Files/Reports/PIP_HealthOnline. pdf.
32 Susannah Fox, Pew Internet: Health, PEW INTERNET (Dec. 16, 2013), http://
www.pewinternet.org/Commentary/201 1/November/Pew-Intemet-Health.aspx.
33 MOBiHEALTHNEWS, WIRELESS HEALTH: STATE OF THE INDUSTRY 2009
YEAR END REPORT 5 (2009), available at http://mobihealthnews.com/wp-content/
Reports/2009Stateofthelndustry.pdf.
34 Mechael & Struble, supra note 2.
njd.
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machines. 6 The advent of mobile health applications has led to
interesting phenomena. Although healthcare providers have been
using various software packages for many years to assist in their
medical determinations, mobile devices can now make actual
diagnoses." The mHealth industry also provides software
applications for healthcare consumers to use.38 The increasing
availability to consumers creates the problem that many may use
these applications for self-diagnosis and treatment.39 In fact, 35%
of U.S. adults report having tried, at least once, to determine
online, whether by computer or mobile phone, what medical
condition they or someone else was experiencing.4 0 38% of these
adults reported that they believed it was something they could
remedy without professional medical attention.4'
Access to mHealth may be an innovative way to provide
healthcare in developing countries where healthcare is sorely
lacking, but in highly regulated countries like the United States,4
unfettered access to healthcare tools raises the concern of when
this crosses the line into practicing medicine and, thus, regulation
of the mIealth tool is appropriate. CTIA-The Wireless Association
("CTIA"),43  an "international association for the wireless
telecommunications industry," and Harris Interactive, a global
custom marketing research firm," conducted a recent survey that
revealed that 78% of U.S. citizens are interested in mobile health
solutions.45 While about 40% of the respondents indicated that
36 See Krouse, supra note 23, at 738.
37 See id.
38 Id at 737.
39 id.
40 Fox & DUGGAN, supra note 31, at 2.
41 Id42
42 Krouse, supra note 231, at 738.
43 The letters C-T-I-A originally stood for "Cellular Telecommunications
Industry Association," and, between 2000 and 2004, they stood for "Cellular
Telecommunications and Internet Association" but now these letters are simply
just part of the name of the organization, "CTIA."
44 CTIA and Harris Interactive Release New National Study; Reveals How
Teens Are Shaping & Reshaping Their Wireless World, PRWEB (Sept. 12,
2008), http://www.prweb.com/releases/CTIA-teen-cell-phone/92008/prwebl3227
54.htm.
45 MOBlHEALTHNEWS, supra note 33, at 2.
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mHealth was an appealing supplement to the healthcare they
receive from their providers, 23% indicated they believe mHealth
could altogether replace visiting a healthcare provider.4 6 If mHealth
supplants professional medical attention, the need for regulation is
obvious.47 Patient safety is at risk.48 Therefore, it is essential that a
device work properly and be used properly to reduce the incidence
of injury. What level of regulation is appropriate has yet to be
determined.
Healthcare providers also find mHealth appealing because of
the cost, time, and effort savings the mHealth industry is creating.49
For example, Glen Stream, the president of the American
Academy of Family Physicians, acknowledges and endorses the
"explosion" of mobile medical apps.so He purports to be an
"iPhone guy," utilizing twenty or so medical or health apps,
stating, "People want to be empowered to take care of their
health."" Nonetheless, he contends that mobile devices and mobile
medical apps "certainly are not going to replace the need for a
collaborative relationship with a family physician."52
A recent report revealed that the United States spent 17.6% of
its Gross Domestic Product in 2010 on healthcare, which is one
and a half times as much as any other country and almost twice
that of the average in a report from the Organization for Economic
Co-operation and Development." The increase in spending on
healthcare is also remarkable. The United States spent $256 billion
46 Id. at 2-3.
47 Krouse, supra note 23, at 738.
48 id
491 Id. at 739.





s3 Jason Kane, Health Costs: How the U.S. Compares With Other Countries,
PBS NEWSHOUR (Oct. 22, 2012), http://www.pbs.org/newshour/rundown/2012/
1 0/health-costs-how-the-us-compares-with-other-countries.html.
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on healthcare in 1980.54 By 1990 the dollars spent reached $714
billion." By 2010 this number almost reached $2.6 trillion.16
Access to mHealth presents a considerable opportunity for
savings in the healthcare industry. In 2009, Verizon Wireless
estimated mobile broadband solutions saved nearly $6.9 billion in
healthcare costs through improved productivity. 7 Further, increased
productivity is expected to save $27.2 billion by 2016." Another
survey polled healthcare providers, patients, payers, and
technology enablers whereby 75% of respondents indicated they
believe that mHealth could cut healthcare expenses by as much as
40%.59
With such potential savings, presumably from several sources
like increased productivity of healthcare providers, reduced time
and effort for both the patient and the provider potentially
translating into better health and fewer office visits and procedures
for patients, it is understandable why there is so much attention on
mHealth. The regulatory environment, as will be seen, is not
properly equipped to propel this impetus. Too much bureaucracy
impedes innovation. mHealth momentum necessitates revision to
the system. While regulation of medical devices is necessary to
ensure safety, the inevitable increase in mHealth and consumer
access requires a more defined, targeted, and streamlined regulatory
scheme for mobile devices in order to keep pace with this quickly
evolving technology.
III. FDA REGULATION OF MEDICAL DEVICES
In order to understand why mHealth requires a more defined,
targeted, and streamlined regulatory scheme, it is necessary to
review the FDA's current regulatory requirements for medical
devices. mHealth products are often comprised of software and
54 U.S. Health Care Costs, KAISEREDU.ORG, http://www.kaiseredu.org/Issue-




5 MobiHealthNews, supra note 33, at 5.
58 Id.
59 d
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sometimes include sensors or attachments for a mobile device. The
products, thus, invite additional layers of scrutiny beyond the
standard medical device requirements. As successive layers are
discussed, it becomes apparent that this is a complex environment,
fraught with generalities and exceptions wherein even a diligent
manufacturer can end up unintentionally out of compliance.
A product that meets the definition of a medical device falls
within the purview of the FDA, and is then subject to regulation
before and after it is marketed.60 Section 201(h) of the Federal
Food, Drug, and Cosmetic Act of 1938 ("FDCA") defines a device
as "an instrument, apparatus, implement, machine, contrivance,
implant, in vitro reagent, or other similar or related article,
including any component, part, or accessory which is . . . intended
for use in the diagnosis of disease or other conditions, or in the
cure, mitigation, treatment, or prevention of disease, in man or
other animals . . . ."" If the device in question is not a medical
device, then no FDA regulation applies. If it is a medical device,
then one must evaluate several layers of regulation to determine
whether certain regulations apply and whether the developer or
manufacturer meets those regulations in offering the product to the
public.
A. Intended Use
A significant threshold inquiry for determining if an article is a
medical device is whether the product in question is intended to
diagnose or treat a disease or condition.6 2 "Intended use" is a
critical element in determining FDA regulation." If an article, like
software, is intended to be used for medical purposes, then the
FDA considers it a medical device.6 4 On the other hand, an article
60 Krouse, supra note 23, at 745.
61 21 U.S.C. § 32 1(h) (2012); see also Is The Product a Medical Device?, U.S.
FOOD & DRUG ADMIN., http://www.fda.gov/MedicalDevices/DeviceRegulation
andGuidance/Overview/ClassifyYourDevice/ucmO51512.htm (last updated Feb.
8, 2013) (setting forth the basic definition of a medical device and distinguishing
it from other FDA regulated products such as drugs).
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is not considered a medical device if it is intended to promote or
encourage general health or wellness;6 5 for example, an application
for diet or exercise information."6
Thus, the initial question is whether the mHealth product is
intended for general health or wellness or whether it is intended to
diagnose or treat a disease or condition.6 7 The distinction is not
always black and white. Along the spectrum, general health and
wellness may begin to bleed into diagnosis and treatment. For
example, an overweight person might use m~lealth products to
assist with an exercise regime and manage diet, which might
otherwise be considered health and wellness. At what point does
managing weight rise to the level of treating obesity? Is that what
the manufacturer of such a health and wellness application
intended?
Related to the concept of "intended use" is "indication of use."
The indication of use designates the parameter for which the
medical device is approved." A company presents this in its
submission for approval to the FDA.69 When the FDA approves the
medical device, it makes public the indication of use."o Consider,
for example, cough medicine. The indication of use is "coughing,
sore throat . . . etc."" These are the indications for which the
product is approved to treat as reflected in the submission
documents and subsequent FDA approval.72 The intended use is "to
treat an infection."73
The FDA derives "intent" from the product's promotional
claims.74 Promotional claims revealing the intended use may be
65 Id.
Krouse, supra note 23, at 760.
67 Pollard & Branham, supra note 4, at 3.
68 Interview with Linda Moore, Director of Operations and Regulatory
Affairs, StatRad, LLC, in Poway, Cal. (Aug. 5, 2013) (notes on file with author).
69 Correspondence from Anil Bhalani, Principal RA Consultant, Extomed,






74 Danzis & Pruitt, supra note 13, at 27.
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found on a product label, in "advertising materials, or oral or
written statements by manufacturers or their representatives."" So,
manufacturers generate the intended use for their products based
on how they promote the product to the public. If the intent is to
promote health, the appliance is not a medical device.76 If the intent
is for medical use, then the appliance is a medical device. But
where does the line for health purposes end and the line for
medical purposes begin? Although intended use is still a primary
focus of FDA regulation, technology may have already evolved to
a point where a different paradigm is warranted. At present, the
principle of intended use drives much of the subsequent regulatory
inquiry. If the intended use is a medical purpose, the article
constitutes a medical device, which then requires the developer to
evaluate what class of injury might arise from that use.
B. Medical Device Classification
Since 1976, the FDA's paradigm has categorized medical
devices in three distinct classes based on the potential health risks
to the public-Class I, Class II, and Class III.77 Medical devices are
assigned a classification based on the level of control needed in
order to provide the FDA with reasonable assurance of the
78product's safety and effectiveness. If a device represents a very
low risk of injury, it is considered Class I and does not require any
premarket approval.79 While most Class I devices are exempt from
premarket notification requirements and regulations for good
manufacturing practices,so there are some general controls that
companies must conduct, such as registering the company with the
FDA, listing the device, paying an annual registration fee, and
7 FDA Final Medical App Guidance, supra note 10.
76 Danzis & Pruitt, supra note 13, at 27.
77Id.
78 Medical Devices, Regulatory Controls, Introduction, U.S. FOOD & DRUG ADMIN.,
http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Overview/
GeneralandSpecialControls/default.htm (last updated Apr. 11, 2013).
Danzis & Pruitt, supra note 13, at 27.
80 General and Special Controls, U.S. FOOD & DRUG ADMIN., http://www.
fda.gov/MedicalDevices/DeviceRegulationandGuidance/Overview/Generaland
SpecialControls/default.htm (last updated Apr. 11, 2013).
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tracking the device's activity.' Bandages, examination gloves, and
hand-held surgical instruments are examples of Class I devices.8 2
Devices that present an intermediate level of risk of injury to
people are considered Class II." The FDA's perspective is that for
Class II devices "general controls alone are insufficient to . . .
assur[e] . . . safety and effectiveness."8 4 In addition to general
controls, Class II devices also require special controls, such as
specified content on labels, adherence to performance standards,
and surveillance of the product in the marketplace.".
New medical devices are typically subject to a "Premarket
Notification" under Section 510(k) of the FDCA.86 The FDA
requires a 510(k) Premarket Notification when one is "[i]ntroducing
a device into commercial distribution (marketing) for the first
time."" "Most Class I devices and some Class II devices are
exempt from the 510(k) Premarket Notification" requirement."
The premarket notification is sometimes colloquially referred to
simply as "5 10(k)."
If a Class II device is subject to the 510(k) requirement, the
manufacturer must file a premarket notification with the FDA to
demonstrate that the device is "substantially equivalent" to another
Class II device already on the market.89 An appliance that is
already legally on the market is called a "predicate device.""
81 Krouse, supra note 23, at 746-47; see also General and Special Controls,
supra note 80.
82 Krouse, supra note 23, at 746.
83 Danzis & Pruitt, supra note 13, at 27.
84 General and Special Controls, supra note 80.
8 Id.
86 Danzis & Pruitt, supra note 13, at 27.
8 Premarket Notification (510k), When a 510(k) is Required, U.S. FOOD & DRUG
ADMIN., http://www.fda.gov/MedicalDevices/DeviceRegulationand Guidance/How
toMarketYourDevice/PremarketSubmissions/PremarketNotification5 10k/default
.htm#when (last updated Jan. 3, 2014).
88 Premarket Notification (510k)-21 CFR Part 807 Subpart E, U.S. FOOD &
DRUG ADMIN., http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/
overview/default.htm#510k (last updated Mar. 5, 2013).
89 Danzis & Pruitt, supra note 13, at 27.
90 Medical Devices, How to Find a Predicate Device, Introduction, U.S. FOOD &
DRUG ADMIN., http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/
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Establishing substantial similarity provides the FDA reasonable
assurance that the device is safe and effective.9' The FDA reviews
the submission to determine whether the documentation
demonstrates that the proposed medical device is substantially
similar to another already marketed device.9 2 If the FDA agrees, it
provides a letter of substantial equivalence to the manufacturer
authorizing the commercial distribution of the product." Powered
wheelchairs, infusion pumps, and surgical drapes are examples of
Class II devices.94
High-risk devices are Class III." These are devices that either
sustain human life or present an unreasonable risk of injury to
humans.96 Because of the risks involved, the FDA does not believe
that general or special controls are sufficient to assure safety and
effectiveness.97 The FDA requires general controls and premarket
approval ("PMA") for Class III devices." While some Class III
devices may be able to receive approval through the 510(k)
process, if there is no predicate device against which substantial
equivalence may be shown, clinical data must be submitted to
support the claims of the device.99 In such cases, a manufacturer is
generally required to perform complex, extensive, and expensive
clinical trials'"0 to produce scientific data that demonstrates the
device is safe and effective for its proposed use.'o' The company
must submit the results in a PMA application to the FDA to review
HowtoMarketYourDevice/PremarketSubmissions/PremarketNotification5 I Ok/uc
ml34571.htm (last updated Dec. 20, 2013).
91 510(k) Clearances Overview, U.S. FOOD & DRUG ADMIN., http://www.fda.
gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClear
ances/510kClearances/default.htm (last updated Jan. 17, 2014).
92 Premarket Notification (510k)-21 CFR Part 807 Subpart E, supra note 88.
9 Id.
94 Krouse, supra note 23, at 747.
95 Id.
96 General and Special Controls, supra note 80.
97 Id.
98 Id.
9 Premarket Approval (PMA)-21 CFR Part 814, U.S. FOOD & DRUG ADMIN.,
http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/overview/
default.htm#510k (last updated Mar. 5, 2013).
100 Danzis & Pruitt, supra note 13, at 27.
'0' General and Special Controls, supra note 80.
MAR. 2014] 375
N.C.J.L. & TECH.
and approve before the company may commercialize the
product.'0 2 Pacemakers, artificial heart valves, and breast implants
are examples of Class III devices."o3
C. Quality System Regulation
Regardless of classification, every medical device manufacturer
is required to comply with the FDA's Quality System Regulation
("QSR").'04 The QSR specifies the special controls and
performance standards required.' 5 The purpose of the QSR is to
maintain a certain level of quality and consistency in the
manufacturing process so that products meet FDA specifications'06
in order to assure the safety and effectiveness of finished
products. 10
The QSR describes what is required, but it does not describe
how to go about meeting those requirements. This is another
example of unclear medical device regulation. It is left to the
medical device company to interpret how much of the QSR is
applicable to its operations, and it determines, for itself, what the
company thinks it needs to do in order to meet the QSR.'o In
102 Danzis & Pruitt, supra note 13, at 27.
103 See Information Sheet Guidance for IRBs, Clinical Investigators, and
Sponsors: Significant Risk and Non-Significant Risk Medical Device Studies,
U.S. FOOD & DRUG ADMIN., available at www.fda.gov/downloads/Regulatory
Information/Guidances/UCM 126418.pdf. 18.1.
'0 Interview with Linda Moore, supra note 68; Food and Drugs, Quality
System Regulation, 21 C.F.R. § 820, available at http://www.accessdata.fda.gov/
scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=820&showFR=1 (last updated
June 1, 2013).
1o5 Correspondence with Anil Bhalani, supra note 69. The FDA quality
systems for regulated products are also called current good manufacturing
practices ("cGMPs"). See Medical Devices, Quality System (QS) Regulation!
Medical Device Good Manufacturing Practices, U.S. FOOD & DRUG ADMIN.,
http://www.fda.gov/medicaldevices/deviceregulationandguidance/postmarketreq
uirements/qualitysystemsregulations/ (last visited Apr. 28, 2011).
106 See Medical Devices, Quality Systems (QS) Regulation/Medical Device
Good Manufacturing Practices, supra note 105.
107 See Introduction to Regulation of Medical Devices: Quality Systems
Regulation, and Good Manufacturing Practice, STAN. BIODESIGN, available at
http://www.stanford.edu/group/biodesign/regulatory/materials/qualityslides.pdf
(last visited Aug. 10, 2013).
08 See Correspondence with Anil Bhalani, supra note 69.
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complying or attempting to comply with the QSR, a company
needs to implement quality systems according to certain
performance standards.
D. Performance Standards
To satisfy special controls, manufacturers are required to
adhere to certain performance standards.'O9 Similar to the QSR, the
FDA's guidance on performance standards provides little direction.
First, the guidelines on performance standards are not mandatory,
but a company must have internal procedures in place and related
documentation that are sufficient to demonstrate safety and
effectiveness if the FDA were to audit or investigate the company
or the product."o Performance standards give the FDA an
indication of the quality and consistency of the manufactured item.
A company may develop its own standards that it believes
sufficiently evidence that the manufacturing process produces a
safe and effective product."'
Many companies deploy the standards established by the
International Standards Organization ("ISO"). ISO standards are
documents that provide requirements, specifications, guidelines, or
characteristics that can be used consistently to ensure that
materials, products, processes, and services are fit for their
purpose." 2 The FDA, however, does not mandate ISO standards."'
Nonetheless, the FDA has come to recognize as acceptable some
ISO standards and some standards from other organizations, such
as the International Electrotechnical Commission, the Association
for the Advancement of Medical Instrumentation, Underwriters




112 Standards: What is a standard?, ISO, available at http://www.iso.org/iso/
home/standards.htm (last visited Aug. 3, 2013).




resources for manufacturers, the FDA posts on its website a
number of FDA recognized standards."'
While no particular standard is required, it behooves a
developer to implement a recognized standard because the FDA
accepts the recognized standards as the "state of the art."ll6 If no
recognized standard is implemented, the company will have to
justify the criteria it used before the FDA and hope that the FDA
accepts the internally crafted standards.117 Performance standards
are required regardless of whether the product is a physical article
or purely software.
E. Software
Software presents a challenge to the FDA. Although software
is not explicitly found in the statute,"' the FDA considers software
to be a device if it is intended to diagnose or treat a disease or
condition.1 19 The FDA addressed software products in a draft
policy document in 1989.120 In it, the FDA expressed its perception
that "computer products . . . are intended to involve competent
human intervention before any impact on human health occurs"
and that a computer program poses less risk to patients because a
medical provider can use clinical judgment to evaluate and
interpret the computer system's output.' 2 ' The FDA, however,
withdrew this draft policy in 2005.122 In 2011, the FDA stated it
115 Recognized Consensus Standards, U.S. FOOD & DRUG ADMIN., http://
www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfstandards/detail.cfm?id=27652 (last
updated Aug. 5, 2013).
116 See Correspondence with Anil Bhalani, supra note 69.
117 See id. Other countries have similar standards requirements and have
similarly adopted certain standards as adequate to demonstrate safety and
effectiveness. Id.
"' See 21 U.S.C. § 321(h) (Supp. 2010).
"9 Danzis & Pruitt, supra note 13, at 27.
120 See id. The document was entitled "FDA Policy for the Regulation of
Computer Products 11/13/89 (Draft)." Id.
121 See id.; see also FDA Policy for the Regulation of Computer Products
11/13/89 (Draft) 3.
122 id.
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could not adopt a single software or computer policy to address
every kind of software or computer driven medical device.123
In 2005, the FDA posted guidelines for software contained in
medical devices, entitled "Guidance for the Content of Premarket
Submissions for Software Contained in Medical Devices"
(hereinafter "Software Device Guidance").124 According to the
FDA, the types of software being regulated are "software
components, parts, or accessories, or are composed solely of
software." 25 Even software alone may be a "software device." 26
Furthermore, the FDA indicates the guidance pertains "to software
devices regardless of the means by which the software is delivered
to the end user[.]"l 27 Therefore, this also applies to mobile medical
applications.128
Similar to, but separate from, the three-class classification
system for medical devices, the FDA requires developers to
consider a three tiered "level of concern" over software from a risk
standpoint: major, moderate, and minor. 12 "Major level of
concern" is where failure or a latent flaw in the software "could
directly result in death or serious injury to the patient or
operator."' 3 0 "Moderate level concern" is when minor injury to the
patient or operator could occur."' "Minor concern" is one in which
software failure is unlikely to cause injury. 3 2 This "level of
concern" inquiry seems redundant. The classification inquiry
already evaluated whether there was a low, moderate, or high risk
of injury to the public in determining whether the medical device
123 Medical Device Data Systems, 76 Fed. Reg. 8637, 8638 (Feb. 15, 2011).
124 Guidance for the Content of Premarket Submissions for Software
Contained in Medical Devices, U.S. FOOD & DRUG ADMIN. (May 11, 2005),
http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Guidance




128 Krouse, supra note 3, at 749.
129 Guidance for the Content of Premarket Submissions for Software Contained






in question belongs in Class I, II, or III. Why the duplicate effort?
Nonetheless, if the medical device contains or consists of software,
this additional layer of inquiry is required.
Moreover, this "level of concern" method is an inexact way of
regulating software because the same piece of software may pose
different levels of risk if used in different ways."' For example, a
person using a weight scale for wellness purposes may not
experience harm if the scale displays an incorrect weight.'34
Nevertheless, that same person may experience a moderate or high
risk if the person is required to notify his/her doctor when s/he
exceeds a certain weight and fails to do so because the scale
displayed an incorrectly low weight.'
There is no formally declared "final" policy.'36 The Software
Device Guidance is still only in "proposed" form."' Despite this
proposed state, the industry follows this as is if it were a formal
regulation, and the FDA treats it as such.' Even with just
proposed guidance, the FDA has classified a number of software
products as Class I and Class II medical devices."' Laboratory
information systems ("LIS"), for example, are categorized as Class
I.140 Picture archiving and communications systems ("PACS") are
ranked as Class II.141
As of February 15, 2011, there is, at least, a final rule on what
is called Medical Device Data System ("MDDS")14 2 software.
MDDS software, which is now classified as Class I, is a product
that transfers, stores, converts, or displays medical device data
without providing analysis, alarms, or active patient monitoring. 14
The FDA issued this final rule on its own volition to downgrade
133 Thompson et al., supra note 12, at 11-13.
134 Id. at 38.
'
35 id.
136 Interview with Linda Moore, supra note 68.
1 Id.
138 Id.
139 Danzis & Pruitt, supra note 13, at 27.
140 Id.
141 Id.
142 Medical Device Data Systems, 21 C.F.R. § 880.6310 (2014).
143 Danzis & Pruitt, supra note 13, at 27.
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MDDS software from its previous classification of Class III, which
generally requires premarket approval, down to Class I, which
typically requires only general controls.'" The MDDS software
classification is a narrow category, covering only those functions
that fit within its definition.14 5
F. Accessories
Many software programs and some mobile applications are
considered "accessories" to medical devices under the FDA's
"accessory rule." 46 An accessory is an article that is targeted at and
sold directly to consumers for use with a parent device. 147 These
accessories are generally subject to the same regulation as the
parent device.'4 8
There is also the concept of a "component" under FDA
regulation.149 An accessory can be differentiated from a component;
consumers purchase accessories, whereas manufacturers purchase
components.' The critical distinction is that the manufacturer of a
program does not bear the regulatory burden for components it
makes, but the manufacturer must bear the burden of meeting FDA
requirements for accessories it makes."'
This Article primarily focuses on accessories. Whether the item
at issue is a software program, like a mobile medical app or an
adapter that attaches to a smartphone, these products are sold
144 See 21 C.F.R. § 880.6310.
145 Danzis & Pruitt, supra note 13, at 27.
146 Accessory Regulation in mHealth, EPSTEIN BECKER & GREEN, P.C., (May 10,
2011), http://nhealthregulatorycoalition.org/wp-content/uploads/2010/06/mrcaccess
guiddraft.pdf.
147Bradley Merrill Thompson, FDA Regulation of Mobile Health, http://
mobihealthnews.com/wp-content/pdf/FDA Regulation of Mobile Health.pdf
(last visited July 27, 2013).
148 Danzis & Pruitt, supra note 13, at 27.
49 Thompson, supra note 145, at 3.
50 Id.
1' Id. For a component manufacturer, components are generally exempt from
FDA regulation because the regulatory burden is borne by the manufacturer that
incorporates the component into another product, which ultimately gets sold to
consumers. An accessory manufacturer, however, must meet FDA regulations
because the accessory gets sold directly to consumers. Id.
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separately from the smartphone. Consumers purchase programs,
apps, and adapters directly and then install them in or attach them
to their smartphones. As a result, the accessory rule is pertinent to
this Article.
The FDA has historically regulated accessories with the same
scrutiny as the parent device based on the presumption that if the
accessory failed, then the parent device might also fail.15 2 The risk
of a software failure as an accessory, however, does not necessarily
mean the function of the parent device is affected. For example, an
application that simply downloads data from a blood pressure cuff
to chart values may not affect the parent device at all.'53 Charting
and analysis, however, might exceed the Class I threshold under
the MDDS rule, which does not allow for analysis, and thus such
an application would otherwise have to satisfy the same Class II
scrutiny as the blood pressure cuff.'54 Fortunately, the FDA appears
to recognize that the accessory rule may not fit all circumstances
just as the proposed software guidance is not one-size-fits-all.'
None of these methodologies-classification, software level of
concern, quality systems, performance standard-however, provides
clear regulation on medical software."' Consequently, developers
still face uncertainty as to whether their software is a medical
device, and, if so, what level of regulation is required.' Not only
152 Danzis & Pruitt, supra note 13, at 28.
153 Id.
I54 Id.
1 Mobile Medical Applications Draft Guidance, 76 Fed. Reg. 50,231, 50,233
(Aug. 12, 2011). In a Federal Register notice dated August 12, 2011, that
announced a public meeting regarding the FDA's draft guidance, the FDA stated,
"[a]n accessory that does not change the intended use of the connected device, but
aids in the use of the connected medical device could be regulated as class I." Id.
Thus, it seems the FDA is considering a lower regulatory standard for such
accessones.
156 Telephone Interview with Anonymous, CEO of U.S. medical device
company (Aug. 7, 2013).
1s7 Krouse, supra note 23, at 752. This has serious financial implications for
mobile medical application developers because, for example, the fees for
premarket notification in 2012 were $4,717, but the cost for submitting a medical
device for premarket approval can exceed $1,000,000, plus user fees of $256,384
in 2012. Devices: General Hospital and Personal Use Devices; Reclassification of
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is the regulation of software unclear, but the regulation of mobile
health applications does not fare much better.
G. Mobile Medical Applications
The FDA acknowledged that mobile devices are integral to
modem life."' It further recognized that not all software or mobile
applications pose the same degree of risk to public health and
safety, and, thus, some may require regulation as medical devices
while others require less regulatory oversight.'" On July 21, 2011,
the FDA issued a draft guidance document entitled "Draft
Guidance for Industry and Food and Drug Administration Staff:
Mobile Medical Applications" [hereinafter "Draft Medical App
Guidance"] in which it proposed regulation of mobile medical
applications.'
In the Draft Medical App Guidance, the FDA set forth a
proposed framework for regulating certain software applications
that perform or enable critical diagnostic or treatment activities.''
The FDA specified in the draft guidance that this "narrowly-
tailored approach" only covers the mobile medical apps it
describes.'62 The draft guidance laid out a number of concepts to
help determine which mobile applications the FDA intends to
Medical Device Data System, 73 Fed. Reg. 7,502 (Feb. 8, 2008) (codified at 21
C.F.R. pt. 880).
158 Vemessa T. Pollard & Joseph W. Cormier, FDA Issues Draft Guidance
Regarding Mobile Medical "Apps," 16 CYBERSPACE L. 18, 18 (Aug. 2011).
'59 Id.
160 See generally FDA Draft Guidance for Medical Apps, supra note 10
(providing background on how the FDA views the industry and setting forth
some definitions, the proposed scope of the guidance, insight into the FDA's
regulatory approach and requirements, and series of examples to further explain
the 6uidance).
16 Pollard & Cormier, supra note 158, at 18.
162 FDA Draft Guidance for Medical Apps, supra note 10, at 12.
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regulate."' It also described which persons or entities would be
treated as "manufacturers" for purposes of these regulations.'"
First, the Draft Medical App Guidance pertained to a "mobile
platform," which is any off-the-shelf commercial handheld platform,
whether or not it has wireless connectivity capabilities."'65 Examples
of mobile platforms are personal digital assistants, tablets, and
smartphones.' 66 Another important concept is a "mobile application,"
which is a software application that can either run on a mobile
platform or a web-based software application that is customized to
run on a mobile platform but is actually executed on a server
somewhere else. 67
Moreover, the Draft Medical App Guidance indicated the
FDA would regulate only a subset of applications.' 61 It concerned
those that "meet the definition of a medical device and [either]
(1) are used as an accessory to a 'regulated medical device' or
(2) transform a mobile platform into a 'regulated medical device.' "169
The FDA calls these "mobile medical apps." 7 0
First, a mobile medical app must meet the threshold question of
whether it is a medical device."' Then one of two conditions needs
to be satisfied. If the mobile medical app is a medical device and is
also an accessory to another regulated medical device, then the
163 Pollard & Cormier, supra note 158, at 18. For example, the Draft Medical
App Guidance provides several definitions for the apps and devices intended to
be regulated. FDA Draft Guidance for Medical Apps, supra note 75, at 7-8. It
summarizes the FDA's regulatory approach. Id. at 12-13. It also provides some
examples of apps intended to be regulated under this guidance. See id. at 18-20.
164 FDA Draft Guidance for Medical Apps, supra note 10, at 8. A "manufacturer,"
for example, is "any person who manufactures, prepares, propagates compounds,
assembles, or processes a device by chemical, physical, biological, or other
procedure," including, among other things, those who repackage or change "the
container, wrapper, or labeling of a device in furtherance of the distribution of the
device from the original place of manufacture." Id. at 8 n.7; see generally 21 CFR
§§ 803.3, 806, 807.




6 1 d. at 5.
169 Danzis & Pruitt, supra note 13, at 27.
170 id.
171 Pollard & Branham, supra note 4, at 2.
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Draft Medical App Guidance applied. The Draft Medical App
Guidance may also have applied where the mobile medical app is
a medical device and transforms a mobile platform, like a
smartphone or tablet, into a regulated medical device.
According to the language of the Draft Medical App Guidance,
a mobile medical app can transform a smartphone into a medical
device. The FDA is already familiar with standard electronic
appliances, including smartphones.'7 2 As with many other electronic
machines, the FDA considers a smartphone off-the-shelf hardware."'
Off-the-shelf hardware and software can be incorporated into a
medical device system, which then brings all of the parts into the
medical device review. So, it is important to understand the impact
of installing a mobile medical app.
Appendix A of the Draft Medical App Guidance included three
non-exhaustive lists of examples of mobile medical apps.'74 A
mobile medical app (1) controls or extends a medical device, such
as remotely accessing vital sign readings of patients at home,
(2) transforms a mobile platform into a traditionally regulated
medical device through attachments or sensors, such as turning a
smartphone into an electronic stethoscope, or (3) allows a user to
enter patient-specific data and generate patient-specific outcomes
using algorithmic methods or processes."
The proposed framework is intended to apply to a "mobile
medical application manufacturer," which is "anyone who initiates
specifications, designs, labels, or creates a software system or
application, whether in whole or from multiple software
components.""' A manufacturer could be an entity or a person who
172 Telephone Interview with Anil Bhalani, supra note 7.
173 Interview with Linda Moore, supra note 68.
174 FDA Draft Guidance for Medical.Apps, supra note 10, at 9.
1s Danzis & Pruitt, supra note 13, at 28. See generally FDA Draft Guidance
for Medical Apps, supra note 10, at 18-20. According to the Draft Medical App
Guidance, this last type includes applications that provide an index or score,
calculate dosage for a specific medication or radiation treatment, or offer
recommendations to aid a clinician with a diagnosis. Id. at 19. These apps are
intended for clinicians and may automate certain tasks or calculations such as a
Glasgow Coma Scale, pain index, Apgar score, or National Institute of Heath
stroke scale. Id. at 20.
176 FDA Draft Guidance for Medical Apps, supra note 10, at 9.
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creates, designs, develops, labels, or modifies a software system to
perform as a mobile medical app.'n This does not apply to those
who just distribute a mobile medical app, like retailers and
distributors who do not conduct any manufacturing activities."'
The FDA proposes four broad categories of mobile medical apps in
the Draft Medical App Guidance that it intended to scrutinize
under its usual medical device schema: (1) applications that
display, store or transmit patient-specific medical device data in its
original format ("Original Format Apps"); (2) applications that
control the intended use, function, modes, or energy sources of a
connected medical device ("Control Apps"); (3) applications that
transform a mobile platform into a traditional regulated medical
device ("Transforming Apps"); and (4) applications that create
alarms, recommendations, or new information by analyzing or
interpreting medical device data ("Creating Apps")."'
Original Format Apps purportedly satisfy the definition of
MDDS, according to the FDA, and therefore are regulated under
the FDA's device classification scheme as Class I.18o As noted
earlier, Class I entails general controls for medical devices, which
requires manufactures to register their companies, list their
products, conform quality systems, and provide the FDA with
adverse event reporting.'8 '
A Control App is considered an accessory to the device to
which it connects or extends, i.e., the "parent" device.'82 These
apps are required to meet the regulation applicable to the parent
device.' For example; if the parent device is a Class II medical
device, the Control App manufacturer must meet these same Class
II requirements.18 4
Transforming Apps "are required to meet the controls that
would apply to the resulting medical device if it were manufactured
I77 Id.
178 Id. at 8-9.
17 9 Id. at 13-15.
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independent of the mobile platform."' For example, a
Transforming App that transforms a mobile platform into an
electronic stethoscope would have to meet the requirements for
electronic stethoscopes, which, in this example, are regulated as
Class II devices.186
1 Creating Apps are also considered an accessory to the medical
device from which it draws its data and creates a new activity or
information, and, thus, are regulated according to that device's
classification.'" One could also imagine that if a Creating App
created something new or had a new property or function that the
parent device or another predicate device does not have, the
Creating App might fall into a higher classification, such as Class
III, and require more stringent regulation than the parent device.
The FDA specifies in the Draft Medical App Guidance that such
guidance is intended only to cover these categories.' It is
uncertain how an app that does not fall into of one these four
categories is to be regulated.
Another aspect of this "narrowly-tailored approach" proposed
under the draft guidance is that the FDA indicated it "intends to
exercise enforcement discretion" with regard to mobile applications
that satisfy the definition of a medical device but do not rise to the
level of a mobile medical app.189 Enforcement discretion means
that the FDA will reserve, but not exercise, the option to pursue
enforcement action against a mobile medical app manufacturer for
violating the FDCA and its regulations.'90 The FDA indicated that
mobile applications that "automate common medical knowledge
available in medical literature" to allow individuals to self-manage
a disease or condition should receive discretion. ' Other mobile




88 FDA Draft Guidance for Medical Apps, supra note 10, at 12.
189 Melnik, supra note 1, at 56.
190 FDA Draft Guidance for Medical Apps, supra note 10, at 4.
'9' Pollard & Cormier, supra note 158, at 3.
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track, or store personal data, but are not essential to patient
diagnosis, treatment, or safety.'9 2
The scope of the Draft Medical App Guidance was limited.
The FDA explicitly stated that the guidance did not cover certain
areas. The guidance did not delve into applications that analyze,
process, or interpret medical data from multiple medical devices. 19 3
The FDA explained that it would issue separate guidance for
this.'94 The draft guidance also failed to address wireless safety,
classification or premarket submission requirements, quality system
requirements, and software that implements quality systems. 95
Again, the FDA purported it would address these areas with future
guidance.196
The Draft Medical App Guidance received considerable
criticism.'9 7 While the mobile app industry was generally pleased
to hear that the FDA would exercise enforcement discretion toward
some apps, the FDA failed to delineate where the threshold of
enforcement discretion occurs.'98 In fact, the Draft Medical App
Guidance generated more questions than answers.' For example,
while the FDA suggests most mobile medical apps will fall under
Class I, which are typically exempt from premarket review, or
Class II, which typically requires 510(k) approval for commercial
distribution, there still lies the possibility that a product will fall in
Class III, which will require the more stringent PMA process.200
On September 25, 2013, however, the FDA issued what is
purportedly the final guidance document on this subject, entitled
"Mobile Medical Applications: Guidance for Industry and Food
and Drug Administration Staff' [hereinafter "Final Medical App






197 Danzis & Pruitt, supra note 13, at 28.
198 Id
199 Id. at 29.
200 Pollard & Cormier, supra note 158, at 3.
201 FDA Final Guidance for Medical Apps, supra note 10.
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Draft Medical App Guidance because the Final Medical App
Guidance offers greater detail on -the types of apps the FDA
intends to regulate, a new section that tries to identify what
applications the FDA will not regulate, and a greater number of
appendices with more explicit examples than the Draft Medical
App Guidance.202 In fact, the FDA provides three pages of
examples in the new Appendix A of mobile apps that are not
medical devices according to the FDA and therefore not subject to
regulation.20 3
The FDA has also reorganized the apps it intends to regulate
from the four categories described earlier into three categories:
gone are the Original Format Apps described above, which are
now conceptually captured in the new Appendix A as apps that
will not be regulated.2 04 Still present, in essentially the same form,
are the Control Apps and Transforming Apps, but with the
Creating Apps now recharacterized as "Mobile apps that become a
regulated medical device (software) by performing patient-specific
analysis and providing patient-specific diagnosis, or treatment
recommendations."20 5 The guidance further states that "[t]hese
types of mobile medical apps are similar to or perform the same
function as those types of software devices that have been
previously cleared or approved."2 06 The non-exhaustive lists of
examples of mobile medical apps has moved from Appendix A to
Appendix C with some more detailed descriptions and possible
product codes that may be applicable to such devices.207 The
addition of possible product codes in the examples may help
developers and manufacturers determine whether a new product
might fall into one of these examples.
202 See generally id.
203 Id. at 20-22.
2 04 id.
205 Id. at 13-15.
206 Id. at 15.
207 Id. at 26-28.
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Some commentators consider the Final Medical App Guidance
"good news for the health care community."208 Nonetheless, the
final guidance instigated similar criticism as its draft counterpart.20 9
For example, Bradley Merrill Thompson, the general counsel for
the mHealth Regulatory Coalition, stated, "[T]he final guidance is
fundamentally like the proposed guidance, and omits some very
important areas."2 10 A few items that Thompson noted are. lacking
are "the definition of what are regulated; disease intended uses
compared to unregulated, wellness intended uses; and the exact
meaning of an accessory to a medical device."2" Moreover, there is
an expanded discussion in the Final Medical App Guidance
regarding FDA enforcement discretion212 and a new Exhibit B
giving examples of mobile apps over which the FDA intends to
exercise enforcement discretion.2 13 This, unfortunately, enlarges the
"murky territory left up to FDA's discretion ... ."214 Consequently,
some of the earlier unknowns persist.
Commentators have not yet remarked on a new twist in the
definition of a "mobile medical app" in the Final Medical App
Guidance, which is the conspicuous addition of the words "is
intended."215 Now a mobile medical app is defined as "a mobile
app that meets the definition of a [medical device] and either is
intended [1] to be used as an accessory to a regulated medical
device; or [2] to transform a mobile platform into a regulated
medical device."21 6 This introduces a new ambiguity, because it is
208 Peter Blenkinsop et al., FDA Final Guidance on Mobile Medical
Applications, LIFE SCIENCES Now (Nov. 22, 2013), http://lifesciencesnow.com/
fda-final-guidance-on-mobile-medical-applications/.
209 Greg Slabodkin, FDA Final Mobile Medical App Guidance Mirrors 2011




212 FDA Final Guidance for Medical Apps, supra note 10, at 16-18.
213 Id. at 23.
214 Diana Manos, 3 Surprises in FDA's Mobile Medical Apps Final Guidance,
Gov'T HEALTH IT (Nov. 6, 2013), http://www.govhealthit.com/news/3-surprises-
fdas-mobile-medical-apps-final-guidance.
215 FDA Final Guidance for Medical Apps, supra note 10, at 7.216 Id. (emphasis added).
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not whether the device actually is used as an accessory or actually
transforms a mobile platform, but whether the developer or
manufacturer intended the device to do so. Whether this or other
uncertainties will be addressed in future guidance remains to be
seen. The FDA has noted it will issue additional guidance.2 17
Congress seems to have provided some motivation for the FDA
to develop and implement more specific direction to the
marketplace when it passed the Food and Drug Administration
Safety and Innovation Act ("FDASIA") on January 3, 2012.218
Section 618 of the FDASIA, entitled "Health Information
Technology," instructs the FDA to confer with the National
Coordinator for Health Information Technology and the Federal
Communications Commission and prepare and post on its website
"a report that contains a proposed strategy and recommendations
on an appropriate, risk-based regulatory framework pertaining to
health information technology, including mobile medical
applications, that promotes innovation, protects patient safety, and
avoids regulatory duplication." 2 19 This report (the "FDASIA
Report") was due in July, 2013.220 Perhaps the marketplace will
soon have greater clarity. As of the date of this Article, however,
the FDA has not yet published this congressionally mandated
report. 22 ' There is no indication as to why this is the case. Despite
the legislated timeframe, it could be months or even years before
the FDA actually responds or takes action.2 22 Until the FDASIA
Report is posted, interested parties must glean insight from the
guidance documents and related discussions.
217 Pollard & Cormier, supra note 158, at 3.
218 Food and Drug Administration Safety and Innovation Act, Pub. L.
No. 112-144 (2012).
2 19 Id. at § 618(a).
220 Id. (stating that the report is due "[n]ot later than 18 months after the date
of enactment of this Act," which was July 3, 2013).
221 Reports and Plans Mandated by FDASIA, U.S. FOOD & DRUG ADMIN.,
http://www.fda.gov/Regulatorylnformation/Legislation/FederalFoodDrugandCo
smeticActFDCAct/SignificantAmendmentstotheFDCAct/FDASIA/ucm356316.
htm (last updated Aug. 20, 2013) (showing four reports mandated by the
FDASIA, but not the specific report referenced here that is mandated by Section
618 of the FDASIA).
222 Interview with Linda Moore, supra note 68.
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What is apparent from pre-existing guidelines is that one must
examine several complex layers: (1) the initial question of whether
the product at issue is a medical device; (2) the product
classification; (3) the corresponding control measures; (4) quality
systems; (5) the applicable performance standards; (6) the software
requirements; and (7) the mobile medical app guidance. As
demonstrated in this discussion, some of these layers are overlapping
and somewhat duplicative. Others are ill-defined and leave much
to the medical device company to figure out. While regulation of
medical devices is necessary to ensure safety, the inevitable
increase in mHealth and consumer access requires a more defined,
targeted, and streamlined regulatory scheme for mobile devices in
order to keep pace with this quickly evolving technology.
It would be helpful to examine the categories of mobile
medical apps that the FDA proposes to regulate against four
different types of mHealth products for smartphones that will
further be defined below-information apps, diagnostic apps,
control apps, and adapters. Before delving into product types, two
tangential regulations will be reviewed briefly below.
H. HIPAA Privacy and Security
While the Health Insurance Portability and Accountability Act
of 1996 ("HIPAA") is not core to this Article's discussion on FDA
regulation, the use of mobile devices for healthcare raises serious
HIPAA issues regarding privacy and security.223 Congress passed
HIPAA in 1996 to, among other things, require protection and
confidential handling of protected health information.224 "Protected
health information" ("PHI") is defined as individually identifiable
health information that is transmitted or maintained in electronic
media or in any other form or media, with certain exclusions.2 25
The entry of mobile devices into healthcare has brought new issues
223 HIPAA as it relates to mHealth could warrant its own separate article.
224 Health Insurance Portability and Accountability Act, CALIFORNIA DEPT.
OF HEALTH CARE SERVICES, http://www.dhcs.ca.gov/formsandpubs/laws/hipaal
Pages/1.00%20WhatisHIPAA.aspx (last visited July 27, 2013).
225 45 C.F.R. § 160.103 (2014).
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of privacy and security with regard to patient information.22 6
HIPAA requires healthcare providers to implement and maintain
certain privacy and security measures with regard to PHI.227 Mobile
communications are not secure because communication between
the users goes through a third party's system, the telecommunication
data carrier.228 Moreover, professional communications may be
audited by the U.S. Department of Health and Human Services.229
The issue is that communications between a patient and
physician are protected under HIPAA.230 When a healthcare
provider receives data from a patient it becomes PHI under HIPAA
and the provider is then required to secure the information pursuant
to HIPAA requirements.23 ' Security measures, such as authentication
and encryption, are needed in order to safeguard PHI.232 Typical
commercial mobile communications lack security protocols unless
the designer specifically incorporates them into the device.233
Nonetheless, electronic measures do not eliminate liability and
responsibility. A survey conducted by the Ponemon Institute 23 4
revealed that 96% of healthcare organizations reported securities
breaches often as a result of a lost mobile device. 23 5 Fines are
imposed on HIPAA violations with penalties increasing under new
HIPAA rules that went into effect on March 26, 2013.236
226 Jim Sheldon-Dean & Vidya Phalke, PhD, Healthcare Going the Mobile
Way!, METRICSTREAM, INC. (Feb. 19, 2013), available at http://info. metricstream.
com/healthcare-mobile-security.html?utm source=Campaigns&utmmedium=
Email&utm campaign=Feb 19 CO healthcare mobile-securityWebinar&Cid=
701500000001zn4&Channel=CO.
227 Health Insurance Portability and Accountability Act, Pub. L. No. 104-191,
§ 201(a)(3)(B)(ii) (1996).
228 Id. § 221.229 Id. § 262.
230 Runkle, supra note 3, at 31.
231 Id. at 30.
232 Id.
233 Sheldon-Dean & Phalke, supra note 226.
234 Ponemon Institute is an organization that conducts independent research on
"privacy, data protection and information security polic[ies]." See PONEMON
INSTITUTE, www.ponemon.org (last visited July 27, 2013).
235 Runkle, supra note 3, at 31.
236 Sheldon-Dean & Phalke, supra note 226.
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There are other implications as well, but HIPAA requires a
separate discussion to do them justice. It is simply raised here to
note the convergence of these two federal schemes, HIPAA and
FDA regulation, within the context of mHealth.237
I. Taxation of Smartphones as Medical Devices
The Patient Protection and Affordability Care Act ("PPACA"),
known colloquially as "Obamacare," was signed into law by
President Obama on March 23, 2010.238 After a bustle of
controversy and challenge, the Supreme Court upheld PPACA
with a 5-4 vote on June 28, 2012.239 PPACA is partially subsidized
through a new 2.3% excise tax imposed on medical devices. 240 The
question has been posed whether mobile applications will be
viewed as medical devices whereby the FDA would have the
ability to tax smartphones and tablets.24 1
This conjecture was set in motion on March 1, 2013, when
Congress sent a letter to the FDA asking for clarification on how
the FDA intends to regulate mobile medical apps.242 The letter
asks, among other things, whether the FDA has "discussed,
prepared, or analyzed the effect of the medical device tax on
smartphones (as well as tablets or similar devices) .... "24 3
237 See generally Runkle, supra note 3 (discussing the increase in physician
use of smartphones, how HIPAA applies to data that a doctor or clinic receives
on or from a patient and communications between a doctor and patient and that
survey reports reveal data breaches often occur from lost mobile phones).
238 See PPACA, Pub. L. No. 111-148, 124 Stat. 119 (2010), amended by
Health Care and Education Reconciliation Act of 2010, Pub. L. No. 111-152,
124 Stat. 1029 (2010) (codified in scattered sections of 26 and 42 of the U.S.
Code).
239 Nat'l Fed'n of Indep. Bus. v. Sebelius, 132 S. Ct. 2566 (2012).
240 Kira Davis, Obamacare Tax on Your Smartphone?, INDEPENDENT JOURNAL
REVIEW (Mar. 16, 2013), http://www.ijreview.com/2013/03/41150-obamacare-
tax-on-your-smartphone/.
241 Id.
242 Letter from Fred Upton et al., Committee on Energy and Commerce, to
Margaret A. Hamburg, MD, Commissioner, U.S. Food and Drug Administration
(Mar. 1, 2013), available at http://energycommerce.house.gov/sites/republicans.
energycommerce.house.gov/files/letters/030113FDAsmartphones.pdf.
243 Id. at 2.
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The issue surfaced because the Internal Revenue Service
("IRS") decided to base its medical device taxing authority on
what the FDA considers a medical device. 2" A "taxable medical
device" is "a device that is listed as a device with the [FDA] under
section 510(j) of the [FDCA] and 21 CFR part 807, unless the
device falls within an exemption from the tax, such as the retail
exemption." 24 5 This tax applies to medical devices sold after
December 31, 2012.246
If the FDA determines that a device should have been listed
with the FDA as a medical device, then the device is deemed to be
listed when the FDA notifies the manufacturer or importer in
writing that the device is required to be listed.24 7 This IRS
deference to the FDA has the effect of transforming the FDA into a
government tax agent.248 While the FDA indicated a smartphone or
tablet would not automatically be taxed as a medical device simply
because it is capable of running a medical application, the FDA
stated it needs to make a determination as to whether smartphones
and tablets are medical devices for tax purposes, 249 and thus
speculation ensued.
The tax situation is troublesome because the excise tax is
imposed regardless of whether the manufacturer makes a profit.250
Further, most device companies are relatively small, typically with
50 or fewer employees. 251 To accommodate this tax, companies
may need to cut costs or pass the cost on to consumers.252 This begs
the question of whether a healthcare savings is actually achieved.
244 Katie McAuliffe, Don't Allow Medical Device Taxation on Smartphones,
Tablets and Apps, THE HILL (Mar. 7, 2013, 10:15 PM), http://thehill.com/blogs/
congress-blog/healthcare/286923-dont-allow-medical-device-taxation-on-
smartphones-tablets-and-apps.
245 See Medical Device Excise Tax: Frequently Asked Questions, INTERNAL
REVENUE SERVICE, http://www.irs.gov/uac/Medical-Device-Excise-Tax:-Frequently
-Asked-Questions (last updated May 22, 2013).
246 id








The logical conclusion is that smartphones should not be taxed
as medical devices. The FDA is familiar with smartphones.
Smartphones are standard devices now, like computer monitors
and keyboards.2 53 These "off-the-shelf" items should not be taxed
as medical devices even if incorporated as part of a system.
Furthermore, when a device or software package is a medical
device, it supposedly may only be sold to a physician or to a
consumer with a prescription from his or her physician.254 No one
needs a prescription to buy a smartphone or a tablet. Therefore, a
standard mobile device ought not to be a medical device for
purposes of the PPACA tax. If a mobile medical app transforms a
standard mobile device into a medical device, just the app should
be subject to the tax, not the off-the-shelf device.
This discussion reveals the federal landscape and is complex.
Unmistakably, government has its attention on mHealth. Through
the FDASIA, Congress has demanded further attention. Although
the FDA has not yet provided the FDASIA Report, further
guidance is likely forthcoming from the FDA and it is hoped that it
will lead to a more nimble system. While regulation of medical
devices is necessary to ensure safety, the inevitable increase in
mHealth and consumer access requires a more defined, targeted,
and streamlined regulatory scheme for mobile devices in order to
keep pace with this quickly evolving technology. 255
IV. SMARTPHONE MHEALTH PRODUCTS
The three categories of mobile medical apps that the Final
Medical App Guidance discusses are still merely a subset of
mobile medical apps.2 56 This leaves out a variety of mHealth
products. If one is to have a better understanding of when medical
device regulation is required for a smartphone or tablet, it is
necessary to be more inclusive in discussing mHealth products that
253 Telephone Interview with Anil Bhalani, supra note 7.
254 Id.
255 While taxation is, also, not core to this discussion on FDA regulation, the
FDA's scheme is implicated, and thus it will be touched upon here so that it is
also not ignored. This taxation subject could also warrant its own separate
article.
256 See FDA Final Guidance for Medical Apps, supra note 10, at 12.
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are designed to work with a standard hand-held apparatus. There
are a number of mHealth products available and in development.
Those designed for mobile devices can be described in four types.
First, there are applications that allow users to find, view, and
read medical information (hereinafter "information apps"). 2" This
first type of product essentially mimics what end users can already
do with personal computers by looking up information on the
Internet or running a software application.258
Second, there are applications that perform a diagnostic
function (hereinafter "diagnostic apps"). This type of product
performs a calculation or analysis and computes a result or
determination. 25 9 This process is typically conducted by a user who
inputs certain data into the application; the process and diagnosis is
then rendered without the mental step of human intervention.2 60
The third type of product is applications that allow the
smartphone to control an unattached medical device (hereinafter
"control apps").
The fourth category includes attachments, sensors, or other
devices that attach to or adapt one's smartphone to perform certain
medical function through the use of the attached accessory,
essentially converting it into a medical device whereby the
attachment enables the smartphone to execute medical functions
(hereinafter "adapters"). As noted, the FDA categorizes these as
"accessories" under the "accessory rule." 261 For purposes of this
discussion, an accessory, in the sense of a physical article, will be
called an "adapter" to designate a physical item that attaches to the
257 Krouse, supra note 23, at 741.
258 See id (explaining how informational applications allow users to look up
medical information and other reference materials similar to looking up
information on a website or in a book).
259 See id at 743 (explaining how some applications now process information
and arrive at decisions that were traditionally mental processes that medical
professionals conducted).
260 Id.
261 See generally EPSTEIN BECKER & GREEN, P.C., supra note 146 (discussing
the FDA accessory rule and when accessory regulation is implicated in mHealth




smartphone; not to be confused with the principle of "accessory"
under the FDA's accessory rule, which includes physical articles
and software. The following is an analysis of FDA regulation on
each of these four categories of smartphone mHealth products.
A. Information Apps
Information apps may have escaped FDA regulation. While the
ability to find, view, and read medical information from one's
mobile phone may be a recent phenomenon, people have been
using personal computers this way for years. Popular web sites like
WebMD, HealthCentral, and WrongDiagnosis.com provide a
variety of medical information and tools for managing health.2 62
The FDA regulates none of these sites. Information apps provide
the same access, but do not appear to fall within the FDA's
definition of a mobile medical app because they do not connect to
a medical device, transform a smartphone or tablet into a
traditionally regulated medical device, or generate patient-specific
data. An information app is a product that is likely not a medical
device, but is more akin to general health and wellness, and
perhaps should be free from regulation.
B. Diagnostic Apps
A diagnostic app is an application that performs a calculation
or function and computes a result or determination without human
intervention, aside from entering the data. Diagnostic apps appear
to fall within the FDA's definition of a mobile medical app
according to the Final Medical App Guidance because these
applications allow a user to enter patient-specific data, apply an
algorithm or formulae, and then output patient-specific results.2 63
Accordingly, the FDA presumably intends to regulate diagnostic
apps under its medical device regime of Classes I-III.2" This may
262 See Medical Information Sites: The Pick of the Best Medical Information
Sites on the Net Today, NETToP20.coM, http://medical.nettop20.com/ (last
visited Apr. 4, 2013) (listing some of the most popular and highest-rated Internet
sites for medical information).
263 Danzis & Pruitt, supra note 13, at 27.
264 Id. at 29.
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seem reasonable; however, diagnostic apps have varying capabilities
and, thus, represent varying levels of risk to consumers.26 5
It would make better sense to regulate diagnostic apps that pose
little health risk to consumers differently than diagnostic apps that
pose a greater risk to consumer health. Different diagnostic apps
perform various types of analyses, and, thus, this type of product
can be broken down into three further categories: clinical analysis,
disease management analysis, and health data analysis. 266
1. Clinical Analysis by Diagnostic Apps
Some commentators contend that basic clinical analysis
programs simply automate well-understood, nonproprietary
clinical algorithms and, thus, present a relatively low risk to
consumers. 26 7 The rationale behind this perspective is that
physicians not only understand how to use the information that
such programs generate, but they are also familiar with the
algorithms and calculations utilized in these applications, and,
thus, would be able to recognize incorrect results, and could arrive
at his or her own mentally derived diagnosis. 268 This allows for
"competent human intervention," which the FDA prefers per its
draft software policy. 269
In such event, the FDA perceives that competent human
intervention provides sufficient safeguard against the diagnostic
application leading to medical error.270 So it appears there is
relatively low risk with such diagnostic apps. This presupposes that
a doctor or other healthcare professional is involved in the process.
If the operator is a layperson with no medical training or medical




268 See id (describing the "competent human intervention" principle the FDA
included in its 1989 draft software policy that physicians are knowledgeable
enough to recognize an incorrect result that a software program might generate).
269 Id. at 27 (noting that in 2005, the FDA withdrew the 1989 draft policy
without comment).
270 Id. at 29.
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Software applications that deploy simple, automated, well-
understood, nonproprietary clinical algorithms have been present
on the Internet for years without regulation.2 7' In fact, the FDA had
an oncology drug-dosing calculator on its own website.272 Other
federal government websites offer similar medical calculators. For
example, the National Heart, Lung, and Blood Institute, offers a
"10 Year Heart Attack Risk Calculator." 2 73 The National Institute
of Diabetes and Digestive and Kidney Diseases offers a glomerular
filtration rate calculator for children and another for adults. 274 The
U.S. Department of Veterans Affairs offers a calculator for
cirrhosis and end stage liver disease as well as other similar
clinician tools. 275 Being available on the Internet, these calculators
are open to the general public.
The mere portability of having this functionality on one's
smartphone, likely, does not warrant any new regulation. That
being said, the mere fact that lay people do have access begs the
question of whether a different requirement should be imposed on
lay people because they lack medical training.
2. Disease Management by Diagnostic Apps
A disease management program also seems to be a low-risk
citegory. Such apps manipulate patient-specific data to help
patients manage a disease according to well-understood guidelines
in conjunction with advice from a healthcare provider. 276 An
example of a disease management diagnostic app is one that "helps
heart disease patients create a diet based on published nutritional
guidelines."277 Commentators think that such apps should receive
271 See id.
272 id
273 Risk Assessment Tool for Estimating Your 10-year Risk of Having a Heart
Attack, NAT'L HEART, LUNG, & BLOOD INST., http://cvdrisk.nhlbi.nih.gov/
calculator.asp (last updated May, 2013).
274 GFR Calculators, NAT'L INST. OF DIABETES & DIGESTIVE & KIDNEY
DISEASES, http://nkdep.nih.gov/lab-evaluation/gfr-calculators.shtml (last updated
Apr. 25, 2012).
275 Algorithms, Screens, Toolkits, U.S. DEP'T OF VETERANS AFFAIRS, http://
www.hepatitis.va.gov/provider/tools/ (last updated Dec. 9, 2013).
276 Danzis & Pruitt, supra note 13, at 29.
277 id
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FDA enforcement discretion because they are intended to operate
in tandem with oversight from a healthcare provider and are not
meant to encourage a patient to self-treat or self-diagnose.278
Disease management diagnostic apps may pose a low risk to a
patient under care. Because these apps can meaningfully improve
public health, perhaps they should be subject to lower scrutiny.
Nonetheless, lower scrutiny on such apps does not account for
those who do not seek or receive medical attention. If a doctor is
involved, risk of injury to a patient is likely low. To regulate based
on the assumption that a healthcare provider is overseeing a patient
misses the incidents where a layperson uses the disease
management app without physician supervision. Should a different
regulation apply based on the user? It is unclear whether
enforcement discretion applies and whether a disease management
app will be regarded as a Class I or Class II medical device.
3. Health Data Analysis by Diagnostic App
Another diagnostic app is a program that downloads medical
device data and utilizes the data for basic disease management.27 9
Health data analysis diagnostic apps might perform charting,
trending, or basic disease-management analysis of data obtained
from a medical device, such as a blood pressure cuff or glucose
monitor.280 As noted earlier, MDDS software "transfer[s], store[s],
convert[s], or display[s] medical device data without providing
analysis, alarms, or active patient monitoring" and such software
falls in Class I due to its low risk.2 8'
Although the MDDS rule is a narrow category,28 2 one
commentator suggests that charting, trending, and basic data
analysis ought to be construed as within the scope of the MDDS
rule particularly because the data, even when provided to
consumers, is intended to operate in conjunction with medical
278 See id. (explaining that basic disease management applications pose a low
risk because a healthcare professional is typically overseeing a patient that is a
user of such application and therefore if an application is intended to be used in
conjunction with medical care it should warrant enforcement discretion).
279 Id.
280 id.
281 Id. at 27.
282 Id.
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283attention, and therefore should be entitled to FDA regulatory
discretion. Such discretion, however, does not provide clarity to
the developer. How is one to know whether the FDA will
determine the app in question must be regulated, and if so, at what
level of scrutiny?
Suppose a product receives enforcement discretion, i.e., is
exempted from medical device requirements because a patient is
being overseen by a doctor. Does this same product then require
different regulation when used by a consumer who is without a
physician? This question cannot be answered by just examining the
device and the manufacturer's intended use of it.
4. Control Apps
A control app allows the smartphone to control a separate
medical device, whether physically or wirelessly. As noted earlier,
some software programs fall under the FDA's "accessory rule." 2 84
Mobile applications that control a medical device are considered
"accessories" and are generally subject to the same regulation as
the parent device. 285 The aspect of control unequivocally implicates
the FDA's concern that if the accessory failed, the parent device
might fail as well. If, for example, a control app freezes, it may not
be able to signal the parent device to turn on, turn off, or adjust its
function at a given interval, and thus the FDA's fear is realized.
The Final Medical App Guidance further indicates that a control
app is subject to medical device regulation because a control app
will connect to a medical device for purposes of controlling the
device.286 Pursuant to the accessory rule, a control app is subject to
the same regulation as the parent device.
283 See id at 29 (explaining that applications that perform these functions are
downloading the data from a regulated medical device and that a medical
professional is supervising the use of that data such that enforcement discretion
is justified).
284 See generally EPSTEIN BECKER & GREEN, P.C., supra note 146 (explaining
the FDA accessory rule and when accessory regulation is implicated in mHealth
products).
285 Id. at 2.
286 FDA Draft Guidance for Medical Apps, supra note 10, at 13-14.
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5. Adapters
There are many products that attach to or adapt a smartphone
to perform a medical function. These products contain software,
but they also consist of a physical apparatus, such as an attachment
or sensor that detects external stimuli for the mobile device to
process. For example, the Schosche myTrek and the Polar
WearLink+ allow one to track and upload one's vital signs to his
or her iPhone or Android phone.287 The iHealth BP3 and the
Withings BPM are two blood pressure monitoring adapters that
allow one to monitor, track, and store blood pressure readings. 2 88
Sanofi's IBGStar blood glucose meter tracks one's glucose,
carbohydrate intake, and the dosage of insulin to be taken.2 89
AliveCor Heart Monitor is a mobile phone case lined with
electrodes that converts an iPhone into an electrocardiogram
("ECG") device to detect irregular heart rhythms that can analyze,
store, and transmit ECG readings.290 The following table illustrates
adapters that allow smartphones to give eye exams, take
ultrasounds, and replace stethoscopes.29 '
Examples of Smartphone Adapters
iHealth BP3 iBG*STAR MIT's Netra AliveCor
blood blood glucose refractive eye Heart Monitor
pressure cuff meter test ECG iPhone
case
287 Daniel P., Smartphones and tablets as medical devices, PHONEARENA.COM




290 Ruane, supra note 50.
29 Daniel P., supra note 287. A full color version of the table is available at
the N.C. J.L. & Tech. website at http://ncjolt.org.
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Many more adapters are in development. For example, a
research team at the University of California Los Angeles is
working on a mobile phone based E. coli sensor that is a
lightweight attachment to a mobile phone's camera for detecting
E. coli in water and other fluids.292 CellScope293 is developing an
otoscope that also attaches to a mobile phone's camera to enable
parents to take a picture of their child's eardrum and then email the
picture to a healthcare provider to check for ear infection.2 94
These and other consumer-oriented devices are part of an
established and growing trend that is revolutionizing healthcare.29 5
What is not revolutionary is the regulatory requirement. Because
adapters are embodied in physical articles, and do not exist solely
as software, they are undeniably devices. The only escape from
FDA regulation is if an adapter can be characterized as a product
for general health or wellness, whereby it would then not fit the
definition of a "medical device."296 An alternative approach is that
many adapters may be able to satisfy the lower regulatory
requirements of Class II or by doing a 510(k) notification if, for
example, a blood pressure cuff adapter is substantially similar to a
standard, pre-existing blood pressure cuff.297 However, some
adapters will inevitably have to satisfy the higher-level Class III
requirements by doing a PMA notification if the adapter is so
innovative that there is no predicate device against which to assess
and demonstrate substantial similarity. In fact, some adapters have
indeed undergone clinical trials to receive FDA approval.2 98
AliveCor's Heart Monitor, for example, has been the subject of
several clinical trials.299
These and other similar advancements show there is a critical
mass building in mHealth. Regulation could use an upgrade so that
292 Ruane, supra note 50.
293 A San Francisco-based company.
294 Ruane, supra note 50.
295 See Smartphone Medicine, REPERTOIRE, http://www.repertoiremag.com/
Article.asp?Id=3980 (last visited Apr. 7, 2013).
296 Danzis & Pruitt, supra note 13, at 27.
297 Id. at 28.
298 Ruane, supra note 50.
299 id
404 [VOL. 15: 359
The mHealth Conundrum
it does not become a bottleneck to innovation, or worse, miss the
mark on consumer safety. As can be seen in these examples, some
mHealth products are perceived as needing less regulation or a
lower level of scrutiny, but they assume a patient is being treated
by a healthcare professional. This same product may pose a higher
level of risk of harm to a consumer using the product on his or her
own without a medical professional. How, then, should the product
be regulated? Does the same product warrant two different
regulatory requirements based on whether a healthcare practitioner
is involved? This would complicate matters further. The inevitable
increase in mHealth and consumer access requires a more defined,
targeted, and streamlined regulatory scheme for mobile devices in
order to keep pace with this quickly evolving technology.
V. IMPROVING MHEALTH REGULATION
It is unclear under which situations mobile medical apps are
subject to the FDA's 501(k) and PMA regimes.oo Further, these
medical device regulations were created during a time when
technologies were developing at a slower pace and were less
accessible to consumers.3 0 ' It is outdated to apply these schemes to
mHealth technologies that are evolving at a rapid pace and are
highly accessible to and often designed for consumers.302 By 2015,
it is estimated that 500 million people worldwide will use mobile
medical apps on their smartphones.303 Regulation needs to improve.
The purpose of the FDA is to protect the public health "by assuring
the safety, efficacy and security of human and veterinary drugs,
biological products, medical devices, our nation's food supply,
300 See generally Thompson et al., supra note 12 (explaining that it is
fundamental to business planning and innovation for companies and investors to
understand "whether a given product requires some sort of premarket clearance
or approval from the FDA").
301 Krouse, supra note 23, at 763.
302 id
303 Ralf-Gordon Johns, 500m People Will Be Using Healthcare Mobile





cosmetics, and products that emit radiation."" Ensuring safety
must be carefully balanced with how much regulation is
necessary.30 Manufacturers, and people in general, want to be free
of regulation.30 6 However, when people or loved ones are injured,
they want the government to step in and regulate the activity that
caused injury.30 ' Balancing goes on inside companies as well,
where ethics and morals intersect with revenue and profit
growth.0
The complexity of the regulatory environment and the
guesswork involved make compliance a challenge for even a
diligent company trying to anticipate what the FDA wants.
Generally companies are out of compliance to some degree
because 100% compliance with all FDA regulation is difficult to
achieve.309 It is when a product is found unsafe or ineffective that
issues arise.3"0 The prevailing thought is that if a company makes
an effort to comply with regulation, that effort will keep an unsafe
or ineffective product off the market."' The discussions and
recommendations here are posed in an effort to help strike that
balance better by examining safety under a better lens that will aid
in determining how much regulation is required.
A. Define the Software Regulation
The FDA needs to clarify some of the confusion pointed out in
this Article. The FDA really should capitalize on its opportunity to
do so in the FDASIA Report. It is high time the FDA creates an
"Office of Software."312 For example, developing an Office of In
Vitro Diagnostics allowed the FDA to develop its expertise in the
areas of fertility and reproduction, 3 3 and thus similarly, the FDA
304 About FDA, FDA.GOv, http://www.fda.gov/AboutFDA/WhatWeDo/default.
htm (last updated Sept. 19, 2013).







312 Danzis & Pruitt, supra note 13, at 29.
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could groom its acumen if it had an office with a more dedicated
focus.
Just as the accessory rule seems to be giving way and the FDA
has already recognized that software requires more than an all-
purpose approach, it would be wise for the FDA to define new
classifications for mobile medical apps that are more tailored to the
characteristics of the application rather than the intended use.314
The MDDS rule classifying all MDDS software as Class I is a
good start in defining categories. Similar rules or classifications are
needed. Rather than squeeze mobile medical apps into the existing
medical device schema, it would be prudent to have a new medical
device regulatory framework specific to mobile medical apps, and
perhaps even for the broader context of software. Clearer
definitions would be helpful. Developers need to understand when
their applications will be regulated as a medical device.3 " The
FDA should draw a more definite line between a health product
and a medical product. Asking for a completely new regulatory
scheme just for mHealth products is probably a bit too aggressive,
and it would be fanciful to expect the FDA to do so. While a new
scheme may be ideal, but unlikely, it is achievable for the FDA to
devise and implement better definitions.
Information apps, as defined above, should not even be
considered medical devices. Because essentially the same
information has been available on the Internet without regulation,
the mere portability of this information on one's hand-held device
should not invite new regulation. Certainly information apps
should not be regulated."'6 Beyond this exemption threshold,
however, the level of regulation needs to be defined.
Apps for general health, wellness, and lifestyle monitoring may
be unassuming, but may pose higher risk than believed. Perhaps
these should not be exempted as some commentators argue. 17
Because many health and wellness apps can go beyond what the
314 sd2
315 Kouse, supra note 23, at 756.
3 I61Id.
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manufacturer intends, these likely need some regulation. Perhaps a
low level akin to Class I devices at a minimum.
Diagnostic apps span a wide spectrum, such that they
obviously require multiple classifications to delineate the
appropriate regulatory regime for each category. Although many
diagnostic apps could be considered Class I, there are certainly
apps whose functionality goes beyond basic clinical or basic
disease management analysis. 31 1 Undoubtedly there will be
diagnostic apps that require either 510(k) approval or PMA
clearance. The FDA needs to provide more specific guidance as to
diagnostic app classification and more specific direction on what
data is required in regulatory submissions so that application
developers will have a better understanding of the FDA's
expectations on such products."' What would be helpful in
developing better definitions and distinguishing health products
from medical products, and products that require regulation from
those that do not, is if the FDA examined the principles that bear
on consumer safety.
B. Target the Focus on Principles Underlying Safety
The primary focus with regard to safety has been on the
performance of mobile medical apps in relation to their intended
use. Discussion of access is given short shrift. Safety
considerations necessarily have to change when the power of
healthcare treatment moves from physicians' hands to the hands of
consumers. In addition, actual use requires at least as much
attention as intended use because safety issues will arise through
what actually occurs in the marketplace as opposed to theoretical
expectations of what a manufacturer purportedly "intended." While
not sufficiently part of the regulatory dialogue, consumer access
and actual use have led to self-treatment and the unauthorized
practice of medicine, which has culminated in marketplace
interposition. The FDA needs to consider consumer access, actual
use, and marketplace interposition in order to improve regulation.
318 Danzis & Pruitt, supra note 13, at 29.
319 d.
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1. Consumer Access
Unless one is a physician, who is able to purchase traditional
medical devices directly, the general consumer needs a
prescription to purchase a traditional medical device, except for a
few medical devices that have become available over-the-counter
and can be found at drug stores.320 That said, there is no pharmacy
equivalent for medical devices. Gatekeeping is up to the device
companies.3 2' Mobile medical apps are readily available, literally at
hand, in the application store of one's smartphone. They can be
immediately downloaded, often for free or sometimes for a fee.
Moreover, mobility has given consumers far greater access to
mobile medical apps than consumers previously had with
traditional medical devices.
Discussions regarding FDA regulation necessarily focus on the
device itself, but more attention also needs to be given to consumer
access, otherwise the system cannot be properly improved.
Consumer access cannot be ignored without undermining the
purpose of the regulation in the first place-safety. One
commentator suggests that the FDA should put the onus on
application stores to prevent mobile medical apps from being
marketed without FDA approval.3 22 This appears to complicate the
relationship between the FDA and the developer by inserting a
middleman. It seems misplaced to foist gatekeeping on a
middleman, who then would have to endure a regulatory burden
not previously felt. Further, it would transform an app store into a
medical device pharmacy. Equally important, placing a regulatory
evaluation requirement on a market participant, like an application
store, rather than the FDA might lead to arbitrary or incorrect
320 See Telephone Interview with Anil Bhalani, supra note 7 (explaining the
prescription requirement the FDA imposes on some medical device in order for
consumers to obtain access to them).
321 See Correspondence with Anil Bhalani, supra note 69 (explaining that
pharmacies act as gatekeepers for the pharmaceutical industry to vet a
consumer's prescription for a drug, thereby confirming physician approval, but
there are no equivalents to pharmacies for medical devices and, thus, companies
must implement internal mechanisms to vet a consumer's prescription).
322 Krouse, supra note 21, at 763-64.
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denial of the developer's product. Such measures have the
potential to stifle innovation.
This is not to say that consumer access should be unbridled
with no gatekeeping mechanisms erected. Some threshold may be
desirable. With traditional medical devices, once approved for a
particular indication of use, the FDA identifies whether the
medical device may be marketed by prescription only or over the
counter.323 If the medical device is prescription only, it is up to the
company that received approval to be the gatekeeper.32 4 There are
no pharmacies for medical devices. The company may choose to
sell only to physicians or through a distribution network that
provides the company some assurance that the product is only
reaching physicians or those receiving physician approval.325 The
FDA leaves it up to the company that is getting the medical device
approved to determine how to manage the prescription
requirement, with an FDA enforcement action as the potential
penalty if the company fails to ensure compliance.326
The manufacturer or developer needs to consider a mechanism
to check for physician or prescription authorization before
allowing download of the mobile medical app. It is the
manufacturer or developer, rather than the app store, who is putting
the mobile medical app on the market. The onus should not be on
the app store. The advice here acknowledges that technological
advancement has changed consumer access, and therefore a
concomitant paradigm shift is needed in order to reexamine
whether the current or forthcoming regulation addresses not only
the technological developments but the practical realities as well.
2. Actual Use
Related to consumer access is the concept of actual use. This is
in contrast to intended use. As noted earlier, it appears the FDA is
becoming more aware that it is questionable whether the principle
of intended use still makes sense when applied to a product that is
deployed for an intended purpose of the manufacturer as expressed
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in its product claims.3 27 However, this does not account for use of a
product in ways beyond what the manufacturer expressly intended.
It also does not account for use of a product in a way that a
manufacturer contemplates but does not expressly state.
Consider, for example, the scale mentioned earlier in the
software "level of concern" discussion. The scale posed no harm to
a person simply using it for general wellness purposes, but if the
person is required to notify his doctor when he exceeds a certain
weight and fails to do so because the scale displayed an incorrectly
low weight, the person may experience a moderate or high risk.328
Assume the manufacturer intended the scale for general health and
wellness. Assume further that the scale is classified as a Class I
medical device being deemed to pose a low level of risk to
humans. The actual use-monitoring for a health condition to
signal when to notify a physician-however, poses a higher health
risk. Does "intended use" properly address patient safety?
The disparity may also exist with mobile medical apps.
Consider the Instant Heart Rate app by Azumio, Inc.329 It is a heart
rate monitor that measures one's pulse.330 It uses the built-in
camera on a smartphone to track color changes on the fingertip that
are directly linked to one's pulse.33 ' Azumio, Inc. claims this is the
same technique that medical pulse oximeters use.332 Further,
Azumio, Inc. touts Instant Heart Rate as a "health and fitness"
app.333 As of March 12, 2012, the Android version alone of Instant
Heart Rate has been downloaded over 10 million times and rated
4.4 out of a 5.0 scale by over 107,979 users.33 4
327 See discussion supra Part III.A.
328 Thompson et al., supra note 12, at 38.
329 See Android Apps, GOOGLE PLAY, https://play.google.com/store/apps/detai
1s?id=si.modula.android.instantheartrate&hl=en (last visited July 28, 2013)
(displaying the Instant Heart Rate app, its maker, its category, some screen





334 Id. The listing installs as 10,000,000-50,000,000. Id.
N.C.J.L. &TECH.
Presumably Azumio, Inc.'s intended use is general health and
wellness. In fact, Google and Apple, Inc. categorize the Instant
Heart Rate app as "Health & Fitness.""' Based on this, Instant
Heart Rate is not a medical device at all. If it were, it is likely a
Class I medical device. Heart monitors, however, are Class II
medical devices.33 6 Pulse Oximeters are also Class II medical
devices.3 With tens of millions of people having Instant Heart
Rate readily available on their smartphones, it is not hard to
imagine some people using Instant Heart Rate as a heart monitor.
Again, does "intended use" properly address patient safety? A
traditional heart monitor requires Class II approval. If Instant Heart
Rate is not a medical device at all, just "intended" for health and
wellness, despite also being a heart monitor, then it does not have
to comply with any FDA medical device requirements.
The iStethoscope app by The Undercover Scientist further
illuminates this discord. The iStethoscope turns a smartphone into
a stethoscope so that one can listen to a heartbeat and view heart
waveforms." Apple, Inc. categorizes the iStethoscope in the App
Store as "Medical."339 The developer, however, stated in the
description that iStethoscope is "intended to be used for
entertainment purposes and as a demonstration of the
technology."34 0 It has a higher category (Medical) than Instant
Heart Rate (Health & Fitness), but it is promoted for a lesser
purpose-not for general health or wellness, but for amusement.
Despite it being a "Medical" category, does "entertainment" allow
33 See id; see also INSTANT HEART RATE-HEART RATE MONITOR BY
AzuMio FREE, available at https://itunes.apple.com/us/app/instant-heart-rate-
heart-rate/id409625068?mt=8 (last visited July 28, 2013).
336 Product Classification, FDA.Gov, http://www.accessdata.fda.gov/scripts/
cdrh/cfdocs/cfPCD/TextResults.cfm (last visited July 28, 2013) (listing each of
the eight results as Class 2 when searching "heart monitor").
3n See Product Classification, FDA.Gov, http://www.accessdata.fda.gov/scripts/
cdrh/cfdocs/cfPCD/TextResults.cfm (last visited Aug. 10, 2013) (listing four out
of five results as Class 2, and one, fetal pulse oximeter as Class 3 when
searching "pulse oximeter").
338 iStethoscope Free, iTunes Preview, APPLE.COM, https://itunes.apple.com/
ca/app/istethoscope-free/id383008092?mt-8 (last visited Aug. 4, 2013).
339 id.
340 id.
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it to escape regulation? Under this rubric iStethoscope is not a
medical device at all. This highlights that consumers may not be
adequately safeguarded against all apps.
The current regulatory terrain for medical devices with its
focus on intended use, not actual use, provides a loophole for
mobile devices because there is no gatekeeping through
prescriptions. The intended use with medical devices is similar to
the concept of label claims with drugs and biologics-the product
claims must coincide with approved uses of the device or drug.
There are strict requirements on what a drug developer may and
may not state in its promotional materials with regard to an
approved drug.34' That industry, however, limits the availability of
pharmaceuticals through prescriptions and pharmacies. Furthermore,
in the drug and biologic markets there is ongoing, heated public
discussion regarding concern over promotion of off-label use.342 In
fact, in recent years, very fierce and high stake litigation has
ensued over off-label promotion of drugs.343
There is no public discussion with regard to off-label use of
mHealth products and less discussion regarding off-label use of
medical devices compared to the prevalence of off-label concern in
the pharmaceutical industry.3" Rather, with mHealth, the FDA
seems more concerned with the intended use as promoted by the
manufacturer. mHealth manufacturers or other parties may not
actually promote "off-label" uses for mHealth products whereby
341 George Lasezkay, Professor of Law, Pharmaceutical Law & Policy Class
Lecture at the University of San Diego School of Law (Feb. 7, 2013) (lecturer's
notes on file with author).
342 id
343 See, e.g., United States v. Caronia, 703 F.3d 149 (2d Cir. 2012); Washington
Legal Found. v. Henney, 56 F. Supp. 81 (D.D.C. 1999); Washington Legal Found.
v. Friedman, 13 F. Supp. 2d 51, 62-75 (D.D.C. 1998).
344 There are enforcement actions with regard to off-label medical devices;
however, the pharmaceutical industry experiences a far greater magnitude of
exposure. For example, device maker AtriCure settled with the U.S. Department
of Justice ("DOJ") for $3.76 million and device company Estech settled for $1.4
million in 2010. Anita Slomski, Off-Label Use of Medical Devices: Out of
Bounds, PROTO, Summer 2010, http://protomag.com/assets/offlabel-use-of-
medical-devices-out-of-bounds. Whereas GlaxoSmithKline settled for $3 billion,
Abbott Labs settled for $1.6 billion, and Pfizer settled for $546 million in 2012
for DOJ off-label charges. George Lasezkay, supra note 341.
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the discussions have not yet arisen. This further highlights the
concern that the FDA should pay more attention to actual use of
mHealth products, which may be different from the uses expressed
in the product's promotional materials.
Medical device regulation inadvertently turns a blind eye to
actual use. The above examples reveal the impact of actual use. A
manufacturer may intend the app to be used for general health and
wellness, i.e., the manufacturer may intend to market a non-
medical device that it believes poses little harm to consumers. This
assumes a noble intent. No doubt some may release a product with
the hope or motivation that consumers will use it at a higher level,
while actually purporting that the intent of their product is for a
lower level use.
Regardless of a sincere intent or clandestine intent, the actual
use may give rise to a different level of risk to the consumer. This
is not to say the manufacturer should be liable for any subsequent
harm. In fact, The Undercover Scientist requires would-be
iStethoscope users to acknowledge a disclaimer in order to activate
the application: "By activating iStethoscope you . .. agree that the
developers of this application will not be held liable for any use of
this device, software and output from the software that results in
equipment malfunction, unlawful behavior, or misdiagnosis of any
medical condition."345 The Undercover Scientist may safeguard
itself with a disclaimer, but does this safeguard the user? This is
not a discussion regarding liability. It is a discussion of risk
assessment. What is meant here is that the risk of injury a
consumer faces is more connected to actual use rather than
intended use. Consumer access and actual use further lead to self-
treatment and the unauthorized practice of medicine.
3. Marketplace Interposition
Marketplace interposition has arisen because concepts such as
consumer access, actual use, self-treatment, and the unauthorized
practice of medicine, are lacking in regulatory debate. Marketplace
interposition is where commerce, in this case technological
advancement, encourages society to tacitly permit self-treatment
345 iStethoscope activation screen on iPhone (screen capture photograph on
file with author).
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and unauthorized practice of medicine through consumer access
and actual use.
Interposition is a legal principle whereby a state exercises its
sovereign power and disregards the authority of the federal
government if the state believes the federal government action is
unconstitutional or exceeds the powers granted to the federal
government. However, the U.S. Supreme Court does not
acknowledge this doctrine.34 6
"Marketplace interposition" means that the commercial
marketplace is effectively rejecting the federal prohibition against
self-treatment and rejecting state prohibition of the unauthorized
practice of medicine. Commercial access and widespread adoption
of the technologies and mHealth products that bestow on an
individual new abilities to provide medical care to one's self and
others essentially creates, or interposes, a right of self-treatment
and condones lay people engaging in some measure of the practice
of medicine. Society is permitting the behavior, in effect, by not
enforcing the prohibition against self-treatment or prohibiting the
unauthorized practice of medicine. This effectively interposes a
new right to self-treatment and permission for lay people to
practice medicine.
As noted earlier, mobile devices can now make actual
diagnoses, and increasing availability to consumers creates the
dilemma that many may use mobile medical apps for self-
diagnosis and treatment.3 47 As also noted, at least according to one
survey, 35% of U.S. adults have used online sources to determine a
medical condition they or someone else had and 38% of these
individuals believed they could treat the disease or condition
without a physician.3 48 No doubt they did, or at least tried.
346 See Cooper v. Aaron, 358 U.S. 1 (1958) (the Supreme Court reinstated a
plan of desegregation rejecting the claim that state officials had no duty to obey
federal court orders explaining that federal constitutional rights "can neither be
nullified openly and directly by state legislators or state executives or judicial
officers[.]"); see also Interposition Doctrine Law & Legal Definition, US
LEGAL.COM, http://definitions.uslegal.com/i/interposition-doctrine/ (last visited
July 28, 2013).
347 Krouse, supra note 23, at 738.
348 Fox & DUGGAN, supra note 31, at 2.
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Americans had a right to self-treatment until the government
took it away in 1914.349 Up until then, citizens could purchase any
medication they wanted from any pharmacy without a prescription
or oversight from a physician."o However, society apparently
believed the masses needed protection against themselves, and,
thus, U.S. citizens lost the right to self-treatment almost 100 years
ago.35'
Americans have a right to autonomy, whereby one may refuse
medical treatment.352 Denizens also have a right to self-
determination, whereby patients may direct the treatment they wish
to receive on their own accord or through a power of attorney
proxy.353 Neither of these rights, however, allow a person to
provide medical care to one's self. At present, there is no right to
self-treatment in the United States. Although government has not
intentionally restored the right to self-treatment, technology seems
to be putting it back in the commoners' hands.
mHealth products might also be used on another person, for
example, one may use his or her smartphone app to diagnose or
treat a spouse or child. Just as one is prohibited from self-
treatment, one may not treat another without risking the
unauthorized practice of medicine. Unauthorized practice of
349 Sheldon Richman, The Right to Self-Treatment, THE FUTURE OF FREEDOM
FOUNDATION (Jan. 1, 1995), available at http://fff.org/explore-freedom/article/
selfitreatment/; see also Kevin A. Carson, The Right to Self-Treatment, MUTUALIST
BLOG: FREE MARKET ANTI-CAPITALISM (May 11, 2005), http://mutualist.
blogspot.com/2005/05/right-to-self-treatment.html; Dave Pollard, The Wisdom of
Patients (and the Right to Self-Treatment), How TO SAVE THE WORLD (May 6,
2005), http://howtosavetheworld.ca/2005/05/06/the-wisdom-of-patients-and-the-
right-to-self-treatment/.
350 Richman, supra note 349.
351 id.
352 See Cruzan v. Dir., Mo. Dep't of Health, 497 U.S. 621, 110 S. Ct. 2841
(1990). The United States Supreme Court determined a competent person has a
constitutionally protected liberty interest to refuse medical treatment. Id. The
Court concluded that the U.S. Constitution grants a competent person a
constitutionally protected right to refuse lifesaving medical treatment including
nutrition and hydration. Id.
353 Right to Autonomy and Self-Determination, US LEGAL.COM, http://health
care.uslegal.com/patient-rights/right-to-autonomy-and-self-determination/ (last
visited July 28, 2013).
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medicine happens when one provides medical advice or renders
treatment without a professional license.35 4 The unauthorized
practice of medicine is a crime in every state." When one provides
care to one's self or another, a deeper question then becomes: what
is the "practice of medicine?"35 6 While definitions vary state to
state, a person typically engages in the practice of medicine when
she or he attempts to diagnose or treat an illness or injury,
prescribes medication, conducts surgery, or declares that she or he
is a doctor." Now that mobile medical apps can actually make
diagnoses, an even more vexing question is: who is practicing
medicine? Is it the smartphone owner, the manufacturer who
created the app, the seller or the device itself? The point here is not
to identify culprits guilty of the unauthorized practice of medicine.
These questions are posed to stimulate cogitation and discourse.
Health education has been on the rise ever since the advent of
managed care. Constant pressure to decrease healthcare costs has
engendered extensive conversation in medical and legal circles
regarding self-care and the need for lay people to become more
active participants in their medical care."5 Society seems to want
consumers to provide some measure of healthcare to themselves,
and likely to others, in the case of a spouse, child, or other
dependent. Government is slowly warming up to this paradigm.
Even the FDA acknowledges mobile devices are staples of modem
convenience.359 Technological advancements have allowed
commerce to surpass government, putting healthcare capabilities
354 Wat is the Unauthorized Practice of Medicine?, FINDLAW, http://health
care.findlaw.com/patient-rights/what-is-the-unauthorized-practice-of-medicine.
html (last visited July 28, 2013).
355 idSId356 Id.
358 See generally How Self-Care Can Help Firms Cut Health Bills, 94
COMPENSATION AND BENEFITS FOR L. OFF. 2 (1994); Michael H. Cohen, A
Fixed Star in Health Care Reform: The Emerging Paradigm ofHolistic Healing,
27 ARIz. ST. L.J. 79 (1995); David I. Shalowitz & Michael S. Wolf, Shared
Decision-Making and the Lower Literate Patient, 32 J.L. MED. & ETHiCs 759
(Winter 2004).
359 Pollard & Cormier, supra note 158, at 18.
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into commoners' hands. Society seems to embrace it. This is
marketplace interposition.
Marketplace interposition is real and cannot be ignored if
practical discussions are to be had regarding the appropriate level
of regulation in mHealth. Society wants access and demands
mobility."o Some commentators argue for less regulation for
certain diagnostic apps that presuppose a person is receiving
medical attention.36 ' The reality is that the risk of injury is higher
for lay people operating without physician oversight. Some
measure of regulation is necessary.
Another question is how much healthcare a layperson should
be allowed to practice. As noted earlier, of the mHealth product
types reviewed, diagnostic apps pose gray areas.6 Regulators can
improve the landscape if they increase their focus on diagnostic
apps and target their discussions on consumer access, actual use,
self-treatment, and unauthorized practice of medicine. Perhaps
when the FDA releases the FDASIA Report, the essence of one or
more of these concepts will be seen in new proposed regulation to
promote innovation. In the meantime, a few practical suggestions
are offered here.
4. Streamline the Framework for Mobile Medical Apps
Regulation has its place to ensure safety. A balance is needed
not to stifle innovation. The FDA is criticized for having a slow
and difficult approval process that weakens the economy by
chilling investment and crippling innovation.3 63 There appears to be
some validity to this argument. With regard to medical devices in
general, time to approval has increased, the number of approvals
has decreased, and investment in medical device companies
dropped 37% from 2007 to 2011.364
360 See CTIA and Harris Interactive, supra note 44.
361 See Danzis & Pruitt, supra note 13, at 29.
362 See supra Part IV.B.
363 Andrew Pollack, Medical Treatment, Out of Reach, N.Y. TIMES (Feb. 9,
2011), http://www.nytimes.com/2011/02/1 0/business/1 Odevice.html?pagewanted=
1& r-0&pagewanted=all.
3 4Id
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The solution that clarifies when mobile medical apps become
regulated medical devices also needs to be designed to bring about
approvals faster and cheaper. Applications are often developed by
very small companies, sometimes with only two people.365 They
cannot afford extensive and protracted clinical trials. Similarly, the
industry is moving so quickly, as displayed by the rapidly
increasing number of mHealth apps and ever-increasing adoption
of smartphones, that developers, not to mention professional and
lay consumers, cannot wait for the plodding FDA regulatory
approval process. What also may occur is that developers might
sidestep seeking approval, whether deliberately or unintentionally,
which defeats the purpose of the regulations-to ensure safety.
Thus, in redesigning the approval process, the FDA needs to
keep pace with the dynamics of the mHealth industry. The FDA
has made some gesture in this direction with the launch of the
Medical Device Innovation Initiative in February 2011,
purportedly to give priority review to the newest medical
technologies and devices. However, this program's "Innovative
Pathway" has been criticized as not being significantly different
from the current medical device regime and the FDA, itself,
admitted this is "not a new regulatory pathway."366 The FDA
suggests approval times might decrease by 50%, but it is an open
question whether mobile medical apps will even be eligible for the
Innovative Pathway."' Again, a more effective approach would be
to establish an approval process specifically for mobile medical
apps. The FDA could implement a preliminary review assessment,
institute an abbreviated approval process and, at a minimum,
reduce the review backlog to improve the process. The following
paragraphs detail these approaches.
365 McAuliffe, supra note 244.
366 Questions and Answers About the Medical Device Innovation Initiative,
U.S. FOOD & DRUG ADMIN. (Feb. 8, 2011), http://www.fda.gov/AboutFDA/
CentersOffices/OfficeofMedicalProductsandTobacco/CDRH/CDRHlnnovation/
ucm242068.htm.
3 Krouse, supra note 23, at 758.
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a. Preliminary Review Assessment
As noted earlier, the FDA indicated it intends to exercise
discretion as to whether it will regulate a mobile medical app.368 To
avoid the uncertainty that developers face, the FDA could develop
a pre-clearance process whereby a developer submits design
specifications of an mHealth app in development so the FDA may
render a preliminary assessment. This review could inform the
developer (1) if the product is a medical device, (2) whether the
app requires regulation, and (3) at what level. Such an approach
could eliminate time and effort spent after the fact by
manufacturers having to respond to FDA warning letters.
Moreover, preliminary assessment would not only provide
direction to developers, but might also encourage developers to
"ask permission" first, rather than proceed and "beg forgiveness"
later.
At present, developers and manufacturers have to assess for
themselves what might be required. Many companies engage
regulatory affairs specialists with medical device experience to
advise them on requirements.3 69 If a company has the resources to
hire a regulatory specialist, a preliminary review assessment could
be conducted in about four hours."' Assume for this exercise a
going rate of $250 per hour for regulatory medical device
specialists.' It would then cost about $1,000 for such a review.
The peril with this approach is that a regulatory affairs specialist is
exercising his or her experience to anticipate what the FDA would
require. While this is a common approach, a better solution as
proposed here is for the FDA to implement a preliminary review
assessment, and preferably for less than $1,000. This would give
developers a more clear and confident path with the advice coming
directly from the FDA. This would likely increase compliance.
b. Abbreviated Approval
Another approach is an accelerated approval process.
Accelerated approval is a familiar concept to the FDA. The drug
368Danzis & Pruitt, supra note 13, at 27.
369 Telephone Interview with Anil Bhalani, supra note 7.
371 id
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industry enjoyed significant advances with the accelerated
approval processes implemented under the Hatch-Waxman Act of
1984 for generic drugs.372 This regulatory regime saved drug
companies substantial costs in developing generic drugs, which
further translated into lower drug prices for consumers and
insurance carriers."' The biologics industry hopes to see similar
advancement and cost savings with biosimilars under the
accelerated approval regime promulgated by the Biologics Price
Competition and Innovation Act of 2009.374 This regime was
enacted into law with the passage of PPACA and given effect by
the U.S. Supreme Court when it upheld PPACA on June 28,
2012."'
Because the FDA has accelerated approval processes in the
drug and biologic arenas, the FDA already has experience
implementing expedited review programs. An accelerated approval
process would reduce costs as it has done in the drug industry,
which is especially important considering mobile app developers
tend to be very small companies. Equally important, expedited
approval might help regulation keep up with innovation.
c. Internal Efficiency
The two previous suggestions are essentially new programs,
however, the FDA could improve the process by simply addressing
its existing inefficiency. At present, it takes the FDA 90 days or
more to review a 510(k) submission.376 This may seem like a short
period of time if one compares this to review of a patent
application at the U.S. Patent and Trademark Office, which may
372 Laurence J. Kotlikoff, Stimulating Innovation in the Biologics Industry: A
Balanced Approach to Marketing Exclusivity, B.U. (Sept. 2008), http://people.
bu.edu/kotlikof/New%20Kotlikoff/ 2OWeb%2OPage/Kotlikoff Innovation in_
Biologics21.pdf.
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374 JUDITH A. JOHNSON, CONG. RESEARCH SERV., FDA REGULATION OF
FOLLOW-ON BIOLOGICS (Apr. 26, 2010), http://primaryimmune.org/ advocacy
center/pdfs/health care reform/Biosimilars Congressional Research Service
Re ort.pdf.
g See Nat'1 Fed'n of Indep. Bus. (NFIB) v. Sebelius, 132 S. Ct. 2566 (2012).
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take years." While the patent is pending, the product is typically
already on the market. Unlike a product whose patent is pending,
manufacturers of medical devices have to wait for FDA approval
before they can place their product on the market. A skilled
regulatory affairs specialist can prepare a 510(k) in about a week.7
Why, then, does the FDA need 90 days to review it?379
Reducing the backlog may take some internal management to
reduce unnecessary work, find efficiencies, and coordinate cross-
departmental functions to facilitate scheduling and create
harmony.3"o This is a practical, realistic, and worthwhile effort. If
regulatory review could be reduced to 30-60 days, it would
motivate industry participants to increase compliance efforts and
improve the perception of the FDA."'
While regulation of medical devices is necessary to ensure
safety, the inevitable increase in mHealth and consumer access
requires a more defined, targeted, and streamlined regulatory
scheme for mobile devices in order to keep pace with this quickly
evolving technology.
VI. CONCLUSION
This Article explored the current and evolving FDA regulatory
landscape of the mHealth business. Particular attention was given
to the emerging but unclear stance of the FDA with regard to the
applicability of the current medical device regulatory regime as it
applies to smartphones, software applications, and adapters, as
well as potential new FDA medical device regulation that may be
forthcoming in light of the FDASIA. This Article recommended a
more targeted focus on the concepts of consumer access, actual
use, self-treatment, and the unauthorized practice of medicine.
Current principles such as "intended use" do not properly address
the underlying regulatory purpose of ensuring safety. Consumers
377 Dennis S. Fernandez & James T. Huie, Strategic Balancing of Patent and
FDA Approval Processes to Maximize Market Exclusivity, ASIA PAC. BIOTECH
NEWS (2003), http://www.iploft.com/PTO-FDA.pdf.
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are availing themselves of healthcare tools, including mHealth
products, to provide medical treatment to themselves and others.
Legislators need to consciously and critically examine the
intersection of the unauthorized practice of medicine with the
growing circumstance that society encourages consumers to
provide healthcare to themselves or others.
The presence of consumer access, actual use, self-treatment,
and the unauthorized practice of medicine along with the lack of
these concepts in public discussion have wrought the phenomena
referred to here as marketplace interposition-when commerce
encourages society to tacitly permit self-treatment and unauthorized
practice of medicine through consumer access and actual use.
Marketplace interposition punctuates the need for regulators to
examine their efforts under a different lens. It is recommended that
the legislative calculus consider a more targeted focus on the
concepts of consumer access, actual use, self-treatment, and the
unauthorized practice of medicine. Each concept bears on patient
safety. These cannot be ignored if practical discussions are to be
had regarding the appropriate level of regulation. Safety cannot be
ensured by looking at just the device. Targeting the right concepts
will yield better solutions.
This Article also recommended streamlining the regulations for
simplicity and consistency. The regulatory landscape could be
streamlined if the medical device classification system governed
the regulatory scrutiny without other duplicative and overlapping
considerations. Other streamlining measures proposed here were a
preliminary review process to allow developers to receive a
perspective from the FDA before a product is developed or put on
the market and an accelerated approval process to move regulatory
review along quicker. Another streamlining measure is simply to
find internal efficiency at the FDA in order to reduce the backlog
on medical device review. Further FDA guidance is expected as a
result of the charge from Congress under the FDASIA for the FDA
to implement measures to promote innovation while maintaining
safety, however, it is unknown at present whether such new
measures will improve mHealth regulation or exacerbate the
existing burden.
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While regulation of medical devices is necessary to ensure
safety, the inevitable increase in mHealth and consumer access
requires a more defined, targeted, and streamlined regulatory
scheme for mobile devices in order to keep pace with this quickly
evolving technology. One must proceed cautiously in light of the
unclear and evolving regulatory terrain. Undoubtedly, more
discussion is forthcoming.
